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Abstract: Shigella spp. are a major cause of morbidity and mortality in the developing 
world, causing over 125 million cases of diarrhea annually. Like many Gram-negative 
pathogens, Shigella utilizes a type three secretion system (T3SS) to manipulate its 
environment. Invasion plasmid antigen B (IpaB) is a hydrophobic translocator protein of 
the Shigella T3SS that is responsible for forming pores in host cell membranes. A 
recently published crystal structure of the soluble N-terminal domain of IpaB
 
was the first 
insight into the structure of IpaB and was used as the starting point of this work. We 
sought to characterize the nature of the interaction of IpaB with other proteins, with 
model phospholipid membranes, and with itself. In the Shigella cytoplasm, IpaB 
associates with a chaperone, IpgC. Co-expression of IpgC with IpaB is also required for 
recombinant protein production in E. coli. The soluble N-terminal domain of IpaB was 
used to study the thermodynamics, stoichiometry, and conformational changes that occur 
as a result of the IpaB-IpgC interaction. Using the N-terminal domain of IpaB overcame 
the complications encountered when using full-length IpaB, which requires detergents to 
remain soluble. Förster resonance energy transfer (FRET) was used to demonstrate a 
conformational change in the IpaB N-terminal domain upon binding to IpgC. The next 
phase of this work examined the interaction of IpaB with model phospholipid 
membranes. Fluorescence quenching with potassium iodide was used to probe how the 
environment of individual residues throughout the IpaB sequence was affected by 
membrane interaction. These studies revealed that regions outside of the hydrophobic 
domain are involved in pore formation. Limited proteolysis experiments helped to further 
determine what regions of IpaB are involved in membrane interaction and several 
truncated forms of IpaB were generated for recombinant protein expression. Among the 
most interesting findings was that the C-terminal 85 residues of IpaB are not required for 
pore formation, and actually may function to regulate pore formation. As a whole, this 
work was used to develop a model of IpaB’s interaction with IpgC and with phospholipid 
membranes. 
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CHAPTER I 
 
 
BACKGROUND AND HISTORICAL REVIEW 
 
Shigella species 
Bacteria of the genus Shigella cause a severe disease in humans that, in the absence of 
supportive care, can lead to death. Shigella infections are spread via the fecal-oral route, usually 
by consuming contaminated water. Flies have an affinity for fecal matter and are known to land 
on human food, thus flies have been implicated in the spread of diarrheal disease.
1,2
 A study by 
the Israel Defense Force found that population-control measures against the common housefly 
(Musca domestica) reduced the incidence of shigellosis by 85%.
1
 In developing countries, 
infections with Shigella can quickly turn into outbreaks due to the absence of public sanitation 
and a lack of clean drinking water. Members of this genus are non-motile, Gram-negative bacilli. 
There are four species within the genus Shigella: dysenteriae (serogroup A), flexneri (serogroup 
B), boydii (serogroup C), and sonnei (serogroup D).
3
 Serogroup A contains 15 serotypes, B 
contains 8 serotypes, C contains 19 serotypes, and D contains only one serotype.
3,4
 Shigella has a 
remarkably low infectious dose of 10-200 organisms due to its acid-tolerance systems.
5
 Once in 
the large intestine, Shigella crosses the epithelial cell barrier, evades the innate immune system
2 
 
and induces its uptake into colonic epithelial cells from the basolateral side.
6
 Once inside the 
epithelial cell the bacterium escapes its vacuole, begins to multiply and spreads directly to 
neighboring epithelial cells without entering the extracellular environment.
7
 Symptoms occur as a 
result of inflammation at the site of infection and include fever, severe abdominal cramping, and 
watery diarrhea.
8
 Within two days, the patient will develop bright-red bloody, mucus-laden low 
volume stools and tenesmus.
9
 Disease severity ranges from relatively minor watery diarrhea to 
complicated, life-threatening dysentery. Dehydration is a life-threatening complication that can 
result in renal failure and death; however, most healthy adults can recover from the infection. 
Hemolytic uremic syndrome can develop if an individual is infected with S. dysenteriae due to 
Shiga toxin production by this species.
10
  
Clinical laboratories typically use MacConkey agar, Hektoen enteric agar, and xylose 
lysine deoxycholate agar to isolate Shigella.
11
 Serological assays are the most reliable means of 
distinguishing between Shigella species. Humans appear to be the natural reservoir for Shigella, 
although intriguing evidence suggests that Shigella can live within the amoeba Acanthamoeba 
castellanii, which could serve as an environmental reservoir.
12
 Shigella has not been found in this 
living arrangement in the environment, however, and this potential association remains 
unconfirmed. Shigella outbreaks have occurred in non-human primate colonies.
13
 Individuals can 
asymptomatically carry Shigella, though the reason for carriage versus disease state is not clear.
14
 
Nevertheless, this phenomenon may explain why Shigella remains endemic in some areas of the 
world.
14,15
 The pathology of Shigella in primates is similar to humans and they have been used as 
animal models in the study of this pathogen. Outside of non-human primates, a reliable model for 
dysenteric disease has not been developed. 
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Discovery of Shigella 
 Kiyoshi Shiga isolated Bacillus dysenteriae in 1898, which distinguished bacillary 
dysentery from amoebic dysentery.
16
 Shigella was initially thought to be a member of a human’s 
natural flora, and that disease occurred when the equilibrium between the host, Shigella, and the 
natural intestinal flora was disrupted.
17
 This theory is similar to today’s understanding of 
Clostridium difficile induction of disease.
18
 The disease produced by Shigella was thought to be a 
result of vascular damage caused by excessive endotoxin release by the pathogen.
17
 It was not 
until the 1950’s when the Congress of the International Association of Microbiologists Shigella 
Commission extensively reviewed epidemiological, physiological, and serological reports of 
bacilli causing dysentery and recommended that the genus be named Shigella and established the 
species subgroups as we know them today.
16
 There are over 40 serotypes of Shigella; infection 
provides only homologous serotype protection, so the need for a vaccine is urgent.
16,19
  
Epidemiology 
 The World Health Organization estimates that there are about 1.7 billion cases of 
diarrheal disease globally each year.
20
 Approximately 1.9 million people die each year as a result 
of diarrheal disease, with about 800,000 of these deaths being in children under five years of 
age.
20
 Shigella causes about 125 million cases of diarrhea and ~14,000 deaths annually.
21
 Ninety 
nine percent of all cases of shigellosis occur in the developing world where S. flexneri is the 
species most commonly isolated, while S. sonnei is most common in developed countries.
22
 In a 
real-time demonstration of this phenomenon in China, Thailand, South Korea and Taiwan, the 
prevalence of S. flexneri has decreased and S. sonnei has increased during the recent economic 
growth in these countries.
23-26
 S. flexneri 2a is the most commonly isolated strain. A recently 
emerged strain, S. flexneri 4c, was the second most-common strain in China over the past ten 
years.
23
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Deaths from shigellosis are rare in developed countries due to greater access to medical 
care. In the developed world, outbreaks can occur among children in daycare and among inmates 
at correctional institutions.
27,28
 Shigella spp. are also known to cause traveler’s diarrhea in people 
who have visited endemic regions of the world.
29
 Those returning from North Africa, South and 
Southeast Asia, and Oceania are at the highest risk.
30
  
 Recent studies challenge the 1.1 million deaths attributable to Shigella reported by 
Kotloff, et al. in 1999. One such study was limited to cases of shigellosis occurring in Asia, and 
reported that approximately 125 million cases of shigellosis occur and only 14,000 of these cases 
are fatal annually.
21
 The reason cited for the recent decrease in the number of Shigella-related 
deaths is the improved overall health of children at the onset of infection.
21
 The availability of the 
measles vaccine may have played a role in the decreased number of deaths, because dysentery 
and measles were often comorbid.
21
 Measles exacerbated the diarrhea caused by Shigella and 
other enteric pathogens, leading to increased mortality.
21,31,32
  
The global enteric multicenter study (GEMS) paired children experiencing diarrhea with 
a healthy control individual, and found that Shigella spp. were the 4
th
, 2
nd
 and 1
st
 leading causes of 
moderate to severe diarrhea in children aged < 12 months, 12-23 months, and 24-59 months, 
respectively.
33
 This study, however, found that Shigella spp. were not associated with an 
increased risk of death relative to the healthy control group.
33
 This finding may be misleading, as 
case-fatality rates of up to 52% have been reported during S. dysenteriae outbreaks.
34
  
 The mortality from diarrheal disease is declining at a rate of ~4% per year, but the 
prevalence of disease has remained high.
33,35,36
 Diarrheal disease is only one aspect of a 
complicated public health scenario in developing countries. It has an impact on long-term 
nutritional status that is associated with stunted growth.
37
 The risk of pneumonia increases by 
1.06% for every day of diarrheal disease in the 4 weeks prior to the onset of pneumonia.
38,39
 The 
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risk of secondary infections can be decreased by promoting hand washing and other personal 
sanitation techniques.
39
 The impact of drinking water quality on diarrheal disease burden is only 
visible when other factors are satisfied first, namely community and personal sanitation.
40
 In very 
poor countries the sanitary disposal of human excrement is not always possible. Providing the 
infrastructure to dispose of waste in a more sanitary way is expected to decrease the diarrheal 
disease burden by 30-40%.
40
 Decreasing the burden of fecal coliforms in drinking water by two 
orders of magnitude would then decrease diarrheal disease incidence by another 40% once 
community sanitation is improved.
40
 Building sewer systems is expensive and not a practical 
solution for underdeveloped countries. Thus, there is a need for a low-cost vaccine that can be 
provided by philanthropic organizations.  
Emergence of antibiotic resistance 
 Multi-drug resistance is a problem for many important human pathogens, and Shigella is 
no exception. One study examined 81 S. flexneri isolates from India, and found resistance to 21 
different antibiotics including many that are considered first line therapy for shigellosis.
41
 Almost 
half of these isolates were resistant to ten or more drugs.
41
 Over 70% of the isolates were resistant 
to second-generation fluoroquinolones (ciprofloxacin, nofloxacin), and 17% were resistant to 
third generation cephalosporins (cefixime, ceftriaxone).
41
 Resistance to tetracycline, 
chloramphenicols, sulfonamides, and gentamycin was noted.
41
 Multi-drug efflux pumps and 
mutations in DNA gyrase and topoisomerase were also major contributors to multidrug resistant 
strains.
41
 
 A review published in 2012 revealed that antibiotic resistance is much more pervasive in 
Asia and Africa than in Europe and America.
42
 For S. flexneri and S. sonnei in Asia and Africa, 
resistance to nalidixic acid has risen from 4% in 2000 to 84% in 2009, whereas the rate has 
remained close to 3% in Europe and America over the same time span.
42
 S. flexneri isolates are 
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also rapidly acquiring resistance to ciprofloxacin in Asia and Africa, from 0.3% in 2000 to 13% 
in 2006.
42
  
 Shigella isolates acquire their antibiotic resistance genes from mobile genetic elements 
identified within islands in the bacterial genome such as R plasmids, transposons, and integrins.
43
 
Class 1 and class 2 integrons have been found within Shigella isolates and contain the genes 
required for resistance to ampicillin, streptomycin, trimethoprim, and streptothricin.
43-45
 S. 
dysenteriae type 1 isolates are typically susceptible to nalidixic acid, ciprofloxacin, and 
ceftriaxone, whereas they are resistant to ampicillin, chloramphenicol, tetracycline, and sulfa 
drugs.
34
  
Recent documented outbreaks in the developed world 
 A clonal outbreak of S. sonnei was reported in Los Angeles, California in May 2012.
46
 
Forty-three cases of shigellosis were reported among members of a private club aged from 54-98 
years.
46
 No deaths occurred despite the severity of the illness; the disease severity was attributed 
to the advanced age of the patients.
46
 Most notably, this was the first reported outbreak of S. 
sonnei with decreased susceptibility to azithromycin in the United States.
46
  
 In North London in 2011 an outbreak of S. sonnei was reported among members of the 
Orthodox Jewish community.
47
 The outbreak was caused by a single strain and lasted a total of 
eight weeks, causing 82 illnesses with no associated mortality.
47
 The cases occurred in both 
children and the parents of young children with daycare centers and schools serving as the 
conduit for transmission.
47
 Genome-level examination of the isolates in this outbreak revealed 
that the isolates were all very closely related, but the strain accumulated up to 7 single-nucleotide 
polymorphisms during the outbreak, though no phenotypic differences were evident.
47
 The length 
of this outbreak was attributed to poor communication between public health officials and 
members of the Orthodox Jewish community.
47
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 In the United Kingdom, an outbreak of S. flexneri 3a among homosexual men was 
reported.
48
 This outbreak started in 2009 and was detected in 2011, causing 381 confirmed 
cases.
48
 This epidemic is ongoing and causing relatively few cases, only 1-7 per month.
48
 The 
continued low-level transmission is due to poor hygiene during and after sex.
48
 A similar outbreak 
of S. sonnei occurred in Tokyo, Japan in late 2011 encompassing five patients; however an 
epidemiologic investigation was not conducted so there may have been more cases.
49
  
Complications 
Hemolytic uremic syndrome 
S. dysenteriae type 1 is associated with a high incidence of severe gastrointestinal 
symptoms and hemolytic uremic syndrome (HUS).
34,50
 Disease progression to HUS results in 
mortality rates of up to 52%.
34
 HUS caused by S. dysenteriae type 1 nearly always occurs in 
young children and is primarily caused by massive production of Shiga toxin.
51
 
Lipopolysaccharide (LPS) is another potential mediator of HUS. LPS was detected in the blood 
of several patients with Shigella-mediated HUS and can induce similar damage to the kidneys of 
rabbits.
34
 Escherichia coli O157:H7 is also noted for causing HUS, but it does not occur 
exclusively within one age group.
52
 Three standard clinical signs are typical of HUS 
development: hemolytic anemia, thrombocytopenia (low platelet count), and elevated serum 
creatinine concentrations.
34
 Classically, HUS is known as a blood clotting disorder in which clots 
preferentially form in the glomeruli of the kidneys.
34
 Decreased serum sodium concentrations 
cause the serum to become hypotonic and may exacerbate hemolysis of red blood cells, especially 
in young children.
34
 Development of HUS is strongly linked to the start of antibiotic therapy four 
or more days after the onset of symptoms.
34
 Furthermore, the choice of antibiotic is important 
when treating S. dysenteriae Type I infections.
53,54
 Clinical outcomes of S. dysenteriae type 1 
treatment with either ampicillin or nalidixic acid were compared, and it was found that HUS 
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occurred at a much higher frequency in the ampicillin-treated patients than the nalidixic acid-
treated patients.
53,54
 Anti-motility drugs are contraindicated in the treatment of dysentery because 
they increase the risk of HUS.
34
 The use of appropriate antibiotics early in the onset of disease 
symptoms is recommended.
34
 Resistance to nalidixic acid has led to its replacement with 
ciprofloxacin as the recommended treatment for shigellosis.
55
  
Reactive Arthritis 
 Reactive arthritis (ReA) is an inflammatory disease of the joints that can be triggered by 
gastrointestinal pathogens including Shigella, Salmonella, Campylobacter, Escherichia coli, 
Yersinia spp. and other gastrointestinal parasites.
56,57
 The disease onset is 1-5 weeks post-
infection, is usually polyarticular and tends to occur in joints of the legs, but can also manifest 
outside of the joints as a mucosal, urethral, cutaneous, or ocular inflammation.
57
 ReA symptoms 
have a broad range of severity, ranging from relatively minor and temporary discomfort to 
chronic, debilitating arthritis.
57
 Incidences of ReA due to Shigella infection are typically 
associated with S. flexneri, but S. sonnei has been implicated as well.
58-61
 ReA may occur in up to 
7% of individuals who recover from infection with Shigella and are uncommon in children.
56
 
Other reported complications include tendonitis, enthesopathy, and bursitis.
56
 Most individuals 
that develop ReA after enteric infection are HLA-B27 positive.
56,62
 Development of irritable 
bowel syndrome (IBS) has been linked to previous infection with an enteric pathogen, with an 
incidence ranging anywhere from 4-32%.
63-66
 Risk factors for post-infection IBS include young 
age, stress, high production of TNF-alpha and low production of interluekin-10 (IL-10).
67,68
 
Clearly, the development of post-infection complications is the result of a complex interplay 
between the pathogen, host, and a multitude of host-specific factors and is the subject of 
continuing research.
56,57,68 
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Virulence Factors 
Type Three Secretion System 
S. flexneri has a type three secretion system (T3SS) that is encoded on a 200 kb virulence 
plasmid composed of ~100 genes.
69-71
 T3SS’s are used by a diverse array of Gram-negative 
pathogens to deliver proteins into the extracellular environment or directly into the target cell’s 
cytoplasm. The Shigella “entry region” is a conserved 31-kb portion of the virulence plasmid 
encompassing 34 genes that encode the T3SS and various effector proteins that are required for 
invasion of host epithelial cells, immune evasion, and intracellular survival.
72-75
 These genes are 
only expressed at 37°C but can be influenced by other environmental factors.
72,76
 Transcription of 
the mxi-spa locus and the first set (early) of effectors is activated by exposure to 37°C, thus 
allowing the bacterium to invade epithelial cells. Secretion of the early effectors frees IpaB and 
IpaC’s chaperone, IpgC.77 IpgC then binds to MxiE and induces expression of the late effector 
proteins.
77
 The entry region of the virulence plasmid contains four distinct functional groups of 
genes: proteins that affect host cell function, structural components of the T3SS, transcriptional 
activators, and chaperones.
72
  
Invasion plasmid antigens (Ipa) B, C and D are essential virulence factors secreted by the 
T3SS. IpaB is necessary for macrophage killing and formation of the translocon pore through 
which effector proteins are injected into the host cell.
78,79
 IpaC induces major actin 
rearrangements by activating small GTPases and is also thought to participate in translocon pore 
formation.
78,80
 IpaD and IpaB control secretion from the T3SS needle tip, and IpaD also serves as 
an environmental sensor by binding to bile salts and recruiting IpaB to the needle tip.
81-84
 Whether 
IpaD possesses a host effector function is unclear.  
Structural components of the T3SS are encoded by two groups of genes: membrane 
expression of ipa (mxi) and surface presentation of ipa (spa) antigens.
85,86
 Genes of the mxi-spa 
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locus are absolutely essential for secretion of all T3SS effector proteins.
78
 Two T3SS-
transcriptional activators, VirB and MxiE, comprise another distinct group of genes within the 
entry region.
87,88
 These proteins regulate various genes in the entry region and in other loci 
throughout the virulence plasmid. The four T3SS chaperones comprise the next group of genes 
within the entry region: IpgA, IpgC, IpgE, and Spa15.
89-91
 IpgC and Spa15 are also transcriptional 
regulators.
92,93
 T3SS effectors that are encoded outside of the entry region, such as the outer 
Shigella protein (Osp) and IpaH families of proteins, help shape the immune response by altering 
host cell transcription.
72
 Intracellular motility via actin polymerization is provided by a set of 
genes located outside of the entry region and, with the exception of VirA, are not secreted by the 
T3SS.
72
  
T3SS’s Role in Invasion 
Shigella has been proposed to initially interact with host cells by binding to CD44 and 
α5β1 integrins within cholesterol-rich membrane raft microdomains.
94,95
 Adherence of Shigella to 
the host cell triggers aggregation of membrane rafts creating a locally high concentration of 
receptors and their signaling components, and induces the preliminary cytoskeletal 
rearrangements necessary for invasion.
96
 The T3SS effector proteins IpaC, IpgB1, IpgB2, VirA, 
IpgD, and IpaA alter the host cell’s cytoskeleton to promote bacterial uptake into the host cell. 
IpaC interacts with small GTPases to form membrane extensions around the bacterium.
80
 IpgB1 
and IpgB2 destabilize cytoskeletal components by mimicking the actions of small GTPases, 
whereas VirA acts through its protease activity.
97-99
 IpgD is a phophoinositide-4-phosphatase that 
hydrolyzes membrane components to ultimately separate the membrane from the cytoskeleton.
100
 
IpaA increases vinculin’s affinity for actin, leading to vinculin capping of actin filaments and 
further disassociation of the cytoskeleton.
101,102
  
 
11 
 
T3SS’s Role in Immune Evasion 
 Before Shigella can invade the host’s epithelium, it must first escape the innate immune 
system. In short, Shigella is ingested and passes through the gastrointestinal tract to the large 
intestine, where it crosses the epithelium via M-cells and is phagocytosed by a macrophage.
103,104
 
Once inside the macrophage Shigella escapes the phagosome
105
 and then induces macrophage 
apoptosis via the T3SS effector IpaB which directly binds to caspase-1.
79,105,106
 Macrophage cell 
death leads to the release of proinflammatory cytokines that trigger the inflammatory response, 
leading to the symptoms of dysentery.
107
 Nonetheless, once freed from the macrophage Shigella 
uses its T3SS to induce its own uptake into host epithelial cells from the basal side.
6
  
Shigella uses its T3SS to lyse the phagosome within 15 minutes of bacterial uptake into 
the epithelial cell.
108
 IpaB, IpaC, and IpaD are all important for phagosome escape, but IpaC may 
play the most pivotal role.
109-111
 The late effector IpaH7.8 is also required for efficient phagosome 
escape, however, its role in the process remains unclear.
112
 Within the host epithelial cytoplasm, 
Shigella secretes numerous proteins via its T3SS that interfere with host cell transcription and 
signaling, thus allowing the bacterium to persist in the epithelial cell cytoplasm and avoid 
detection by the immune system. IpgD promotes host cell survival by setting off a signaling 
cascade that activates the serine-threonine kinase Akt.
113
 Another unknown T3SS effector also 
inhibits apoptosis within the epithelial cell.
114
 OspF simultaneously interferes with intracellular 
pathogen detection systems by dephosphorylating MAPK, thus inhibiting MAPK-mediated 
signaling.
115,116
 In the absence of MAPK signaling the transcription of pro-inflammatory genes is 
greatly reduced.
117
 Further down-regulating the inflammatory response, OspG promotes the 
proteolytic degradation of the transcription factor NF-κB.118 IpaH9.8 can even act as an ubiquitin 
ligase, thereby destroying downstream components of the MAPK kinase-dependent pathway.
119
 
In the cytoplasm, Shigella grows, divides and spreads cell-to-cell using actin-based motility.
72
 
VirA degrades microtubules in front of the bacterium, while the intracellular spread protein (Ics) 
12 
 
A localizes to and nucleates actin from one pole of the bacterium, thus creating an actin tail to 
propel the bacterium through the cytosol.
120-122
 The bacterium creates membrane bulges into 
neighboring cells at tight junctions, which then endocytose the protrusion leaving the bacterium 
surrounded by a double membrane.
123
 The double membrane is then lysed in a T3SS-dependent 
manner and the bacteria perpetuate the cycle of intracellular growth and intercellular spread.
111,124
 
 
Toxins 
Shiga Toxin  
 Shiga toxin was first described in S. dysenteriae and is the “original” member of the 
Shiga toxin family.
10
 Several homologous toxins, referred to Shiga toxins 1 and 2, are present in 
various strains of E. coli, most notably strain O157:H7.
10,125,126
 Shiga toxins are AB5-type toxins, 
where the toxic A subunit is enzymatically active and the non-toxic B subunits bind to the target 
receptors.
10
 The A subunit’s C-terminus is inserted into the center of the pore formed by the 5 B 
subunits.
127,128
 The B subunit binds to the glycosphingolipid Gb3 resulting in uptake of the toxin 
complex into target cells.
129
 After uptake, the enzymatically active, 27.5 kDa A1 fragment is 
released upon cleavage by the intracellular protease furin.
130
 Eventually the A1 fragment enters 
the cytosol where it displays single-site RNA N-glycosidase activity, thereby inactivating 
ribosomes through the removal of a single adenosine from the 28S rRNA of the 60S ribosomal 
subunit.
131
 Inhibition of protein synthesis leads to apoptosis of the intoxicated cells.
132
 How Shiga 
toxin reaches the kidneys is poorly understood. The most likely scenario is that the secreted toxin 
enters the bloodstream from the intestine via the bloody lesions that are the result of shigellosis.
34
 
Free Shiga toxin has never been found in the blood, but it has been observed to bind with low 
affinity to polymorphonuclear leukocytes via the A subunit and could reach its target in this 
way.
133
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Enterotoxins  
Four enterotoxins are encoded by S. flexneri: ShET1 (setAB), ShET2 (sen), Pic, and 
SepA.
134
 Collectively, these enterotoxins are thought to cause electrolyte secretion into the small 
intestine, contributing to the watery diarrhea that often accompanies shigellosis.
134
 What 
advantage Shigella would gain by increased fluid level in the small intestine is unclear, but it has 
been proposed that this may expedite transit to the colon where Shigella actually causes disease.
72
 
ShET1 and Pic are encoded on the bacterial chromosome, whereas ShET2 and SepA are encoded 
on the Shigella virulence plasmid.
134
 ShET1 is only found in S. flexneri 2a and 2b, whereas 
ShET2 is found in most serotypes of S. flexneri as well as in S. boydii, S. sonnei, S. dysenteriae, 
and enteroinvasive Escherichia coli.
135-137
 ShET1 is an A-B type toxin, but the stoichiometry 
remains undefined.
137
 ShET2, also known as OspD3, is secreted via the T3SS.
138
 ShET2 is found 
in 80-90% of all Shigella isolates tested that also retained the virulence plasmid.
139
 ShET2 
increases the amount of the pro-inflammatory cytokine IL-8 secreted post-invasion by cultured 
epithelial cells.
140
 The prevalence of these toxins does not appear to follow any geographical 
pattern. The molecular mechanism of action of ShET1, ShET2 and SepA is poorly understood; 
however Pic has been studied in some detail. 
Pic (Protease involved in colonization) is a member of the serine protease 
autotransporters of Enterobacteriaceae (SPATEs) family, class 2 that binds to and cleaves 
proteins modified with Sialyl Lewis-X (SLeX)-O-glycans.
141
 SepA is also a SPATE that 
contributes to the enterotoxicity of Shigella, but its target remains unknown.
134
 Pic is involved in 
colonizing the mucosal epithelium, cleaves mucin and induces mucin release.
141,142
 This toxin is 
only expressed in S. flexneri 2a.
141
 Pic may be involved in immunomodulation because it cleaves 
many cell-surface O-linked glycans (e.g. CD43) that are involved in leukocyte trafficking.
141
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Deletion of ShET1, ShET2, and Pic resulted in a live-attenuated vaccine that does not 
cause watery diarrhea, thus solving a problem that has plagued vaccine development.
143
 Live-
attenuated vaccines are effective at inducing homologous serotype protection, but they are noted 
for a lack of cross-protection against distinct serotypes. Therefore, the need for a universal 
vaccine candidate is urgent.
143
 An intriguing finding was that this live-attenuated vaccine also 
generates very high titers to antigens conserved across all Shigella species, namely IpaB, IpaC, 
and IpaD.
143
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CHAPTER II 
 
 
INVASION PLASMID ANTIGEN B (IpaB) FROM SHIGELLA FLEXNERI UNDERGOES A 
CONFORMATIONAL REARRANGEMENT UPON INTERACTION WITH ITS 
CHAPERONE IpgC 
Introduction 
Shigella’s ability to invade human cells depends on the insertion of a functional 
translocon pore into host cell membranes. Pore formation is impossible without the translocators 
Invasion plasmid antigen B (IpaB) and IpaC. IpaB is a hydrophobic, 62 kDa protein that has been 
demonstrated to form pores in model membranes.
144
 Invasion plasmid gene C (IpgC) is a 17.8 
kDa, α-helical chaperone protein that maintains IpaB and IpaC in a soluble, secretion competent 
state within the bacterial cytoplasm prior to secretion via the T3SS.
91,145-147
 IpgC is classified as a 
class II T3SS chaperone that has a tetratricopeptide repeat (TPR) fold.
145,146
 After IpgC releases 
the translocators, it forms a transcription-activating complex with MxiE, specific for late T3SS 
effector proteins.
91,92,148
 Degradation of IpaB occurs when ipaB is expressed in the absence of 
IpgC and this applies both to expression in Shigella or recombinant expression in Escherichia 
coli.
91,144
 When in a complex with IpgC, the translocator proteins are unable to interact with 
membranes.
144
  
Others have proposed that IpaB possesses two separate chaperone-binding sites (CBS’s) 
within the N-terminus, where CBS 1 spans residues 16-35 and CBS 2 spans 51-70.
149
 The authors  
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of that work speculated that the presence of two CBS’s indicates that two IpgC molecules bind to 
a single IpaB molecule, thereby forming a heterotrimer.
149 
This claim was based on the 
identification of the two separate CBS’s in a co-crystal structure of an IpgC dimer in complex 
with a 56-residue IpaB peptide encompassing both CBS’s.149 The aforementioned study 
contributed valuable knowledge to the field, however, the IpaB peptide used represents less than 
10% of the total length of IpaB. Furthermore, IpgC binding to IpaB as a dimer conflicts with 
existing literature demonstrating that IpgC and IpaB interact at a 1:1 stoichiometry.
144
 
Full-length IpaB can be recombinantly expressed in large quantities, but in order to 
maintain solubility it must be co-expressed with its chaperone IpgC.
144
 The 6x His-tagged IpaB-
IpgC complex can then be purified by immobilized metal affinity chromatography. Mild 
detergents can be used to irreversibly separate IpaB and IpgC.
144
 Separation is irreversible 
because IpaB requires the presence of detergent to remain soluble, yet the presence of any 
detergent was not compatible with their reassociation. Attempts to reconstitute the IpaB-IpgC 
complex after separation with mild detergents failed, at least in part because complete removal of 
detergents led to precipitation of the IpaB (Adam, P. R. unpublished results). Fortunately, a 
soluble N-terminal fragment of IpaB was identified by limited proteolysis, which could 
potentially be used to explore the IpgC-IpaB interaction. This fragment was also used to solve a 
crystal structure of the IpaB region spanning residues 74-224.
150
  
With a stable N-terminal fragment of IpaB in hand, we were thus in a position to carry 
out a detailed analysis of the interaction between IpaB and IpgC. There have been no previous 
studies concerning the structural consequences of this important interaction. We first used 
fluorescence polarization (FP) and isothermal titration calorimetry (ITC) to demonstrate an 
interaction between the IpaB N-terminal fragments and IpgC. Then we explored the 
stoichiometry of the IpaB-IpgC interaction by chemical-crosslinking. Finally, we explored the 
possibility of a conformational rearrangement within the IpaB N-terminal fragment using Förster 
17 
 
Resonance Energy Transfer (FRET). The results from this study contributed to our developing an 
understanding of one of the most important protein-protein interactions that occurs to allow the 
process of type III secretion. 
Results 
Identification of the IpaB N-terminal domain 
M. L. Barta et al. used Subtilisin-A to carry out limited proteolysis of the IpaB-IpgC 
complex (Figure 1.1). Tandem mass spectrometry was then used to identify proteolytically stable 
bands.
150
 IpaB fragments were selected and cloned for recombinant protein expression based on 
predicted solubility, including IpaB
1-226
, IpaB
28-226
, and IpaB
1-94
.
150
 Each of these fragments were 
stably expressed in the presence of IpgC; however, only the two larger fragments could be stably 
expressed in the absence of IpgC. IpaB
28-226
 was then used by M. Barta et al. to obtain a crystal 
structure for the internal fragment IpaB
74-224 
(Figure 1.2).
150
 The crystal structure revealed a >100 
Å coiled-coil and was structurally homologous to the pore-forming toxins colicins E3 and 
Ia.
150,152,153
  
IpaB
1-226
 and IpaB
28-226
 could be stably expressed in the absence of chaperone or 
co-expressed with IpgC, indicating that they were excellent candidates for exploring the 
nature of the interaction between IpaB and IpgC. IpaB
28-226 
separated from IpgC during 
later chromatographic purification, so no information is presented for this co-purified 
complex. On the other hand, IpaB
1-226 
and IpaB
1-94
 remained associated with IpgC 
throughout the entire purification protocol. IpaB
1-94
 was unstable in the absence of IpgC 
and thus no data concerning this fragment were collected. 
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Figure 1.1: Limited Proteolysis of the IpaB-IpgC Complex.
151
 Full-length IpaB-IpgC was 
incubated with increasing concentrations of subtilisin A for 60 min. Band 1: Full-length IpaB. 
Definite identification of bands 2, 3, and 4 was not possible, but they may represent progressive 
degradation from the C-terminus of IpaB. Band 5 represented a proteolytically stable domain and 
was identified by LC-MS/MS as IpaB
28-226
. Band 6: Full-length IpgC. This work was done by M. 
L. Barta.
151
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Figure 1.2. Crystal Structure of IpaB
74-224
.
150,151
 Cartoon representation of the crystal structure 
of IpaB
74-224
 solved at 2.1 Å resolution. The structure consists of a 120 Å long coiled-coil. W105 
is identified in this figure, as are the N- and C-terminal residues. This figure was prepared for 
Adam et al., 2012
151
 according to the crystal structure solved by Barta, et al., 2012.
150
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Secondary structure content and stability analysis 
 Far-UV circular dichroism (CD) spectroscopy was performed on the highly purified 
proteins listed in Table 1.1. The spectra of all IpaB fragments and their IpgC complexes 
possessed strong minima at 222 nm and 208 nm, indicating dominant α-helical secondary 
structure content (Figure 1.3A).
151
 This was in good agreement with the published crystal 
structure of IpaB
74-224 
(Figure 1.1).
150
 CD was also used to examine the thermal stability for the 
folding of these IpaB fragments (Table 1.1).
151
 The CD signal at 222 nm was monitored as a 
function of temperature to determine if the structural stability of the IpaB N-terminal domain was 
affected by the presence of IpgC (Figure 1.3B). Transition temperatures (“Tm”) were defined as 
the midpoint of any observed transitions, and indicate the temperature at which the α-helical 
secondary structure content and disordered structure content are approximately equal. IpaB
1-226
 
and IpaB
28-226
 both unfolded at 57.5° C, whereas IpgC unfolded at 45° C. The IpaB
1-94
-IpgC 
complex had the highest Tm of 62.5° C. The co-purified IpaB
1-226
-IpgC complex displayed two 
transitions, each near the Tm of the component proteins. This suggests that the dimeric complex 
dissociated and each protein unfolds independent of the other. This is in contrast to the single 
elevated Tm observed for IpaB
1-94
-IpgC where the proteins may lend structural support to each 
other.  
In Vitro Interaction between IpgC and N-terminal IpaB fragments: 
Since the isolated IpaB N-terminal domain co-purified with IpgC following recombinant 
expression in E. coli, the in vitro interaction between these proteins was explored. Fluorescence 
polarization (FP) is a technique that can indicate changes in the molecular volume of a 
fluorescent species which influences the rotational diffusion (how quickly a molecule is rotating) 
of that molecule.
154
 The rate of rotational diffusion is inversely related to the size of the molecule, 
with small molecules rotating quickly and large molecules rotating more slowly. This 
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Table 1.1. Molecular Weights and Thermal Stability of Proteins Used in this Chapter.  
Protein    Molecular Mass (kDa)  Tm (°C)
151
 
IpaB
1-226
   25.1 (50.2)
a
   57.5 
IpaB
28-226
   22.3 (44.6)
a
   57.5 
IpgC    17.8 (35.6)
a
   45.0 
IpaB
1-226
-IpgC   42.9    45.0/60.0 
IpaB
28-226
-IpgC   40.1    ND
b 
IpaB
1-94
-IpgC   27.7    62.5     
 Theoretical molecular masses (kDa) and thermal stability of the proteins and protein 
complexes used in this study. 
a
Mass of the homodimeric complex is shown in parentheses. 
b
The 
IpaB
28-226
-IpgC complex dissociated during purification, thus no thermal stability data are 
available. 
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Figure 1.3. CD Spectra and Thermal Unfolding.
151
 Proteins were dialyzed against citrate-
phosphate buffer, containing 150 mM NaCl, pH 7.0. Panel A: CD spectra were collected from 
200-260 nm following the parameters in materials and methods. Panel B: The CD signal at 222 
nm was monitored as a function of temperature (10 to 85° C) using the parameters in materials 
and methods. Both panels: IpgC (closed circles); IpaB
1-226 
(open circles); IpaB
1-226
-IpgC (closed 
triangles); IpaB
28-226 
(open triangles); IpaB
28-226
-IpgC (closed squares); IpaB
1-94
-IpgC (open 
squares). 
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phenomenon can be harnessed to explore protein-protein interactions. We expressed and purified 
IpaB
1-226
 and IpaB
28-226
 with an N or C-terminal Cys residue (designated by the N or C in front of 
the residue numbers in each fragment name) to allow for fluorescent labeling at a single site using 
the sulfhydryl-reactive dye fluorescein-maleimide (FM). FM-IpaB
N1-226
, FM-IpaB
C1-226
, FM-
IpaB
N28-226
, and FM-IpaB
C28-226
 were incubated with increasing concentrations of unlabeled IpgC 
(Figure 1.4). The milli-polarization (mP) values were plotted as a function of IpgC concentration 
and analyzed with SigmaPlot (Systat Software Inc., San Jose, CA), which also calculated the 
dissociation constant (Kd; Table 1.2). The correlation coefficient (R
2) was ≥ 0.94 for each plot. 
The Kd’s for FM-IpaB
N1-226 
and FM-IpaB
C1-226
 were 199 nM and 60 nM, respectively. Conversely, 
the Kd’s for FM-IpaB
N28-226 
and FM-IpaB
C28-226
 were 411 nM and 501 nM, respectively. These 
data indicated that IpaB
1-226
 interacts with IpgC more strongly than does IpaB
28-226
. This 
relationship was not altered by the location of FM on the N- or C-terminus (Figure 1.4). These 
data are consistent with the previous report that IpaB’s N-terminal 25 residues contain a CBS that 
is distinct from a CBS located C-terminal of residue 28.
149
 The presence of both chaperone 
binding sites is not necessary for IpaB-IpgC interaction, but the interaction is strongest when both 
sites are present within a single polypeptide.  
To explore the thermodynamic parameters of the IpaB-IpgC interaction, isothermal 
titration calorimetry (ITC) was used in the laboratory of Dr. Brian Geisbrecht in parallel with our 
fluorescence polarization data (Table 1.3). ITC is fluorophore-independent and can be used to 
calculate the Kd, ΔH, ΔS and stoichiometry of interaction (N). The Kd’s in Table 1.3 agree well 
with those derived from FP experiments, where IpaB
1-226
 was shown to have greater affinity for 
IpgC than IpaB
28-226
. The ITC and FP data indicate a 14-fold and a 2 to 8-fold stronger affinity of 
IpaB for IpgC when both CBS are present, respectively. ΔH and ΔS are positive in both cases 
indicating that these interactions are endothermic and entropic (Table 1.3). Interestingly, the ITC  
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Figure 1.4. FP with IpaB fragments.
151
 Panel A: FM-IpaB
N28-226
 (open circles, R
2
 = 0.99) and 
FM-IpaB
N1-226
 (solid circles; R
2
 = 0.94). Panel B: FM-IpaB
C28-226
 (open circles; R
2
 = 0.99) and 
FM-IpaB
C1-226
 (solid circles; R
2
 = 0.99). 80 nM solutions of the FM-labeled IpaB fragments were 
prepared with increasing concentrations (0 to 1 µM) of unlabeled IpgC. SigmaPlot was used to fit 
a single-site saturation binding curve to the data. Error bars = standard deviation. 
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Table 1.2. Fluorescence Polarization Derived Dissociation Constants for the IpaB N-
terminal Domain and IpgC.
151
         
Protein     Kd (nM) 
IpaB
N1-226
    199.4 ± 62.6 
IpaB
C1-226
    59.5 ± 5.6 
IpaB
N28-226
    410.9 ± 14.2 
  IpaB
C28-226
    500.7 ± 77.1      
IpaB fragments labeled at either the N- or C-terminus were prepared at 80 nM while unlabeled 
IpgC was titrated up to a concentration of 1 µM. Data were plotted as an (x,y) scatter and fit to a 
single-site saturation ligand binding equation using SigmaPlot (Figure 1.4). Dissociation 
constants (Kd) were derived from the equation.  
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Table 1.3. Isothermal Titration Calorimetry Reveals Thermodynamic Properties of 
Interaction Between IpaB N-terminal Domain and IpgC
151
      
Parameter  IpaB
1-226
  IpaB
28-226
 
N   1.03 ± 0.01  0.88 ± 0.02 
ΔH (kcal / mol)  8.68 ± 0.14  3.55 ± 0.11 
ΔS (J/K)  59.7   37.2 
  Kd (nM)  210 ± 50  2960 ± 530     
The thermodynamic properties of IpaB-IpgC interaction were monitored by isothermal titration 
calorimetry in the laboratory of our collaborator Dr. Brian Geisbrecht. Stock solutions of IpaB
1-226
 
(600 µM) and IpaB
28-226
 (1.569 mM) were injected 6 µl at a time into 1.456 ml IpgC (30 µM and 
48 µM, respectively). N = stoichiometry of the interaction; ΔH = change in enthalpy; ΔS = change 
in entropy (Joules / Kelvin); Kd = calculated dissociation constant. Errors represent standard 
deviations of three independent measurements. 
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data suggested a 1:1 stoichiometry between IpaB and IpgC, which fits with the original 
observations of Birket et al.
144
 
Stoichiometry of the IpaB-IpgC Interaction 
IpgC is known to form homodimers in solution
146
 and this is consistent with the structure 
of other class II T3SS chaperones, such as SycD from Yersinia enterocolitica.
155
 This structure 
did differ somewhat from another report on the dimeric structure of a truncated form of IpgC, 
however, the latter structure included a small fragment of IpaB as part of the structure.
145
 The 
work by Lunelli et al. provided conflicting evidence as to whether IpgC remains a dimer while 
complexed with IpaB.
144,145,149
 To examine this translocator-chaperone complex more closely, the 
stoichiometric relationship between the IpaB N-terminal domain and IpgC was investigated by 
using the homobifunctional cross-linking agent dithiobis[succinimidyl propionate] DSP. First, co-
purified IpaB
1-94
-IpgC and IpaB
1-226
-IpgC were cross-linked (Figure 1.5A).
151
 Co-purified IpaB
1-
226
-IpgC formed a cross-linked product of approximately 40 kDa, which agrees well with the 
expected mass of 42.9 kDa for an IpaB
1-226
-IpgC heterodimer (See Table 1.1 for molecular 
masses).
151
 Co-purified IpaB
1-94
-IpgC formed a cross-linking product of 25 kDa, also indicative of 
heterodimer formation.
151
 
As a control in these cross-linking experiments, each protein was incubated alone with 
cross-linking agent. When this was done, we found that each protein formed complexes having a 
mass that is consistent with homodimer formation (Table 1.1 and Figure 1.5B & C).
151
 It should 
be noted that in all cases, the sizes of the observed homodimers and heterodimers were 
sufficiently different to distinguish them by SDS-PAGE. Because of this and the suggestion by 
others that IpaB may interact with IpgC at a 1:2 ratio, the IpaB fragments (except for IpaB
1-94
) 
were mixed with IpgC at a 1:2 molar ratio (IpaB:IpgC) and then incubated with DSP.
151
 A two-
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Figure 1.5. Crosslinking of IpaB N-terminal fragments and IpgC.
151
 Proteins were chemically 
cross-linked using the disulfide-containing agent DSP. DSP cross-linking can be reversed by 
using reducing agents. Panel A represents co-purified IpaB
1-94
-IpgC and IpaB
1-226
-IpgC. 
Dithiotheritol (DTT) was used to reverse cross-linking and its presence is indicated at the top of 
each panel. Panel B (IpaB
1-226
) and Panel C (IpaB
28-226
) depict cross-linking using independently 
purified IpaB
1-226
 or IpaB
28-226
 and IpgC. These proteins were mixed at a molar ratio of 1:2 
(IpaB:IpgC). The left- and right-most lanes in Panel B depict cross-linking of individual proteins 
as labeled. Panel C is similar to B, except IpaB
28-226
 was used. Asterisks = IpaB homodimers; 
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Continued (Figure 1.5 legend) 
 
arrowheads = IpaB-IpgC heterodimer; thin arrows = IpgC homodimers. The numbers on the left 
side of each panel indicate the molecular weights (in kDa). 
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fold molar excess of IpgC was used to ensure that IpgC could still form a dimer in case the 
addition of IpaB disrupted IpgC homodimer formation. SDS-PAGE analysis revealed that IpaB
1-
226
 and IpaB
28-226
 co-incubated with IpgC formed 40 kDa and 38 kDa complexes, respectively 
(Figure 1.5B & C).
151
 These masses were once again consistent with heterodimer formation. 
Interestingly, a 35 kDa cross-linked product was present in both conditions, which is consistent 
with the continued presence of IpgC homodimers following formation of the IpaB-IpgC 
heterodimer.
151
 No IpaB homodimeric products were detected in any of the samples, indicating 
that all of the IpaB molecules had formed heterodimeric complexes with IpgC.
151
 Since IpgC was 
present at a twofold molar excess, the consistency by which IpgC homodimers formed suggested 
that IpaB and IpgC form a heterodimer.
151
 Taken together with the cross-linking analyses of co-
purified full length IpaB-IpgC,
144
 the data suggest that IpaB forms a 1:1 heterodimer with IpgC in 
vitro and in vivo.  
The heterodimeric complexes formed by IpaB and IpgC are smaller than the IpaB N-
terminal domain homodimers, yet paradoxically there was a rise in mP values observed when 
IpgC was added to the IpaB samples (Figure 1.4). Decreases in molecular volume generally lead 
to decreases in mP values, however, the flexibility within the region to which the fluorophore is 
attached can have a significant impact on the observed mP value. Decreased flexibility of the 
termini as a result of IpgC binding would readily explain the rise in mP values seen upon 
heterodimer formation. To explore this, FP experiments were performed using IpaB’s native Trp 
at position 105 (Figure 1.6). It is unlikely that the region surrounding W105 is flexible since it is 
located within the long coiled-coil of IpaB. When IpgC was titrated into non-fluorescent IpaB
28-
226
, a decrease in polarization values was observed, with the smallest FP values observed at an 
eqimolar concentration of these proteins. Taken together, the FP, ITC, and cross-linking data 
presented here strongly support our proposal that an interaction occurs between the IpaB N-
terminal domain and IpgC and that this interaction gives rise to a heterodimer.
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Figure 1.6. Fluorescence Polarization (FP) using Native Trp Within the Coiled-Coil of 
IpaB
28-226
.
151
 FP measurements obtained during titration of IpgC into IpaB
28-226
 were obtained 
using IpaB’s intrinsic W105 as the fluorophore. IpgC does not contain any Trp residues and thus 
did not interfere with the measurements. 3 µM IpaB
28-226
 was required to obtain a reliable 
fluorescence signal. The X-axis is shown as the molar ratio of IpgC:IpaB. Samples were excited 
with plane-polarized 295 nm light and emission was monitored at 340 nm.  
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Förster resonance energy transfer (FRET)  
FRET is a technique that allows distance determinations within macromolecules with 
precision approaching the Angstrom level. It is a molecular ruler that relies upon using two 
different fluorophores, a fluorescence donor and a fluorescence acceptor. The donor’s emission 
spectrum must overlap with the acceptor’s absorption spectrum, which allows the donor’s 
excitation energy to be directly transferred non-radiatively to the acceptor fluorophore.
154
 This 
results in quenching of the donor’s emission. The extent of this quenching depends upon the 
spectral properties of both probes and with an efficiency that is inversely proportional to the 
distance between the donor and the acceptor.
154
 In our application, we used FRET to determine if 
conformational changes occur in the IpaB N-terminal domain upon binding to IpgC. The donor 
fluorophore used was the native tryptophan residue (W105) located within the N-terminal region 
of IpaB and the acceptor was an extrinsic dye, Alexa Fluor 350 (Alexa350) covalently linked to 
the sulfhydryl moiety of the N- and C-terminal Cys residues alluded to above. It should be noted 
that there are no interfering Trp residues within IpgC. This FRET pair has an Ro of 21 Å.
156
 Ro is 
the distance between the probes’ dipoles at which 50% energy transfer would be expected to 
occur, and it depends upon the spectral overlap and absorption properties of the donor, along with 
the assumption of random orientation of the dipoles.
154
 IpaB
N1-226
, IpaB
C1-226
, IpaB
N28-226
, and 
IpaB
C28-226
 were labeled with Alexa350-maleimide. IpaB
C1-226
 became unstable when labeled with 
Alexa350, which precluded collection of fluorescence spectra for this protein. Alexa350-labeled 
IpaB fragments were incubated with or without 1 µM IpgC. To calculate the FRET efficiency in 
each case, the spectrum of the donor only sample (IpaB lacking the Alexa350 label) was collected 
with and without IpgC. The donor only spectrum was then compared to the spectrum for 
Alexa350-labeled IpaB with and without IpgC. Representative fluorescence spectra for the 
unlabeled and Alexa350-labeled IpaB fragments alone and in the presence of IpgC are shown in 
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Figure 1.7. Maximum donor emission was determined based on these spectra and used to 
calculate the FRET efficiency (Table 1.4) as described in the Materials and Methods section.  
The fact that these IpaB N-terminal fragments form homodimers complicated the 
confidence in the calculation of distances. In a homodimer of IpaB, there would be two Trp’s and 
two Alexa350 moieties for the donor plus acceptor samples, thus making it difficult to distinguish 
intermolecular FRET from intramolecular FRET within the homodimer as long as it remains 
intact. Nevertheless, we calculated distances based on the fluorescence measurements with this 
caveat in mind. The results of the FRET calculations are shown in Table 1.4. Based on the crystal 
structure for IpaB
74.224
 (PDB entry 3U0C),
150
 the distance between W105 and A224 is ~18 Å, 
which agrees well with the calculated FRET distance in IpaB
C28-226
 of 17 Å in the absence of 
IpgC. We were unable to determine a precise distance between W105 and the N-terminus of IpaB 
in the crystal structure because the extreme N-terminus of IpaB was not resolved.
150
 
The data for IpaB
N1-226
 indicated that a large decrease in FRET efficiency occurred after 
the addition of IpgC, which resulted in an approximate 10 Å increase in distance between the 
donor and acceptor probes. Addition of IpgC to IpaB
N28-226
 did not result in a significant change 
FRET efficiency. When IpgC was added to IpaB
C28-226
, a measureable decrease in FRET 
efficiency occurred, resulting in a modest 4 Å increase in distance. Because of homodimer 
formation, the FRET data cannot unequivocally demonstrate that a conformational change occurs 
within the IpaB N-terminal domain upon IpgC binding; however, when taken together with the 
FP data, a strong argument can be made for a conformational rearrangement occurring in IpaB 
upon chaperone binding. 
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Figure 1.7. Representative Fluorescence Emission Spectra used to Calculate Intramolecular 
Distances by FRET.
151
 The Trp residue within unlabeled IpaB
N1-226
 (Donor only, D) or 
Alexa350-labeled IpaB
N1-226
 (Donor/Acceptor, D/A) was excited at 295 nm and the resulting 
spectra are shown above. Spectra were collected in the presence and absence of 1 µM IpgC. 
Unlabeled IpaB
N1-226
 with and without IpgC (dark and open circles, respectively); Alexa350-
IpaB
N1-226
 with and without IpgC (dark and open circles, respectively). Spectra were normalized 
to IpaB
N1-226
 + IpgC.  
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Table 1.4. Förster Resonance Energy Transfer (FRET) Efficiencies and Calculated 
Distances.
151
            
 
       0 µM IpgC   1 µM IpgC   
Protein  FRET Efficiency
a
 Distance
b
 FRET Efficiency
a
 Distance
b
 
IpaB
N1-226
  37.6 ± 3.3  22.8  6.5 ± 3.6  32.8 
IpaB
N28-226
  47.1 ± 3.2  21.4  37.9 ± 14.8  22.8 
IpaB
C28-226
  74.5 ± 5.9  17.6  46.1 ± 6.8  21.6  
 a
FRET efficiencies (%) were calculated using Equation 1 (see Materials and Methods 
section) after determination of the quenching of the Trp (donor) emission in the presence of 
Alexa350. 
b
The apparent distance was then calculated based on Equation 2 (see Materials and 
Methods) and it is given here in Angstroms.  
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Conclusions 
Previous studies identified a highly soluble domain (the “N-terminal” domain) of IpaB 
that was used to solve a structure from residues 74-224.
150
 Because this soluble N-terminal 
domain contained the proposed sites required for IpaB binding to its chaperone (IpgC), it was 
used to study the interaction between IpaB and IpgC. This has been previously impossible 
because the stable expression of full-length IpaB requires co-expression with IpgC, thus yielding 
an IpaB-IpgC complex that cannot be reconstituted after dissociation. The continued presence of 
the detergent used to separate IpaB and IpgC is necessary to maintain IpaB as soluble and makes 
the reassembly of the complex impossible. Studying all aspects of the structural features of IpaB 
is important for identifying methods for blocking its function, especially since recent findings 
have suggested that IpaB exists in many functional oligomeric and conformational states that may 
be relevant to function during infection.
157,158
 This chapter features three main findings. First, the 
N-terminus of IpaB interacts strongly with IpgC and the strength of this interaction is affected in 
an additive manner by the presence of both chaperone binding sites (CBS’s). Secondly, IpaB and 
IpgC are in a homodimeric state that is dissociated in favor of the more energetically favorable 
heterodimer when the two are mixed. Finally, the N-terminal domain of IpaB appears to undergo 
a conformational change upon binding to IpgC, and it is presumed that this change is related to 
how IpgC is able to maintain full-length IpaB in a membrane-inactive and soluble state prior to 
IpaB secretion. 
Building off of the partial crystal structure described by Barta et al.,
150
 we expressed and 
purified the soluble fragments IpaB
1-94
, IpaB
1-226
 and IpaB
28-226
.
151
 These fragments, except for 
IpaB
1-94
, do not require IpgC for stable expression, however, they can be co-purified with IpgC. 
The IpaB
28-226
-IpgC complex dissociated during the purification process, perhaps because of the 
high ionic strength conditions used in some of the later purification steps, though it is unclear 
why the complex remained intact after the high salt conditions used in the IMAC chromatography 
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process but separated during size-exclusion chromatography (P.R. Adam and M. L. Barta, 
personal communication).
151
 Nevertheless, the IpaB
1-94
-IpgC and IpaB
1-226
-IpgC complexes 
remained intact throughout all purification steps and were analyzed by CD spectroscopy, as were 
individually purified proteins except for IpaB
1-94. All of the proteins were highly α-helical. The 
IpaB
1-226
-IpgC complex appeared to separate prior to unfolding due to the presence of two 
transitions. In contrast, the single transition of the IpaB
1-94
-IpgC complex suggests that this 
complex remained intact until both proteins unfolded simultaneously. IpaB
1-94 
may have a 
stabilizing effect on the secondary structure of IpgC. This may be due to an alternate 
conformation adopted by IpaB
1-94 
that increases the affinity of these two proteins for one another.  
As stated above, IpaB
28-226
-IpgC separated during purification, whereas IpaB
1-226
-IpgC 
remained intact, implying a stronger interaction exists between IpaB
1-226
-IpgC than between 
IpaB
28-226
-IpgC. IpaB’s N-terminal domain was proposed to contain two CBS’s (CBS 1 = residues 
16-35, CBS 2 = 51-70),
149
 so a stronger interaction may exist when both CBS’s are present. Thus, 
we investigated whether the IpaB N-terminal domain could interact with IpgC in vitro using 
complementary techniques: fluorescence polarization (FP) and isothermal titration calorimetry 
(ITC). For the FP experiments, we genetically introduced a single Cys at either the N- or C-
terminus of IpaB
1-226
 and IpaB
28-226
 and fluorescently labeled the proteins with the sulhydryl-
reactive dye fluorescein maleimide (FM). FP experiments suggested an interaction between 
IpaB’s N-terminal domain and IpgC, so we further investigated that interaction using ITC with 
the help of our collaborators in the laboratory of Dr. Brian Geisbrecht. Data from both techniques 
indicated that IpaB
1-226
 had a lower Kd than IpaB
28-226
 for IpgC interaction, indicating that IpaB 
had a higher affinity for IpgC when both CBS’s were present. IpaB28-226 contains only one 
complete CBS and does not interact as strongly with IpgC, supporting the two CBS hypothesis. In 
the case of the ITC data, a 14-fold higher affinity was observed when both IpgC binding sites 
were present, versus a 2 to 8-fold increase based on the FP experiments. ITC data also indicated 
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that this interaction was energetically favorable and suggested a 1:1 stoichiometry between IpaB 
and IpgC. Based on these findings, we investigated the stoichiometry of binding in more detail.  
Using chemical cross-linking, the Picking laboratory previously demonstrated that the 
two translocator proteins (IpaB and IpaC) interact with IpgC at a 1:1 stoichiometry.
144
 Another 
group later proposed that there are two separate CBS’s in IpaB and speculated that two IpgC 
molecules bind to one IpaB molecule.
149
 We sought to address these conflicting findings, and thus 
designed chemical cross-linking experiments using purified IpaB fragments, IpgC, and the co-
purified IpaB
1-94
-IpgC and IpaB
1-226
-IpgC complexes. These data agreed with previous findings 
from the Picking laboratory and strongly suggested a 1:1 stoichiometry between IpaB and IpgC. 
IpaB
1-226
, IpaB
28-226
, and IpgC all formed homodimers when purified independently, which agrees 
well with independent crystallographic studies where IpaB’s N-terminus and IpgC each 
crystallized as homodimers.
145,146,149
 Furthermore, we incubated IpaB
1-226
 (possessing both CBS’s) 
and IpaB
28-226
 (possessing only one CBS) with a two-fold molar excess of IpgC and found that the 
products consistently had the molecular mass of the expected IpaB-IpgC heterodimer, and that the 
excess IpgC remained as a homodimeric complex. These data indicate that in the presence of both 
CBS’s each IpaB molecule binds only one IpgC molecule. The thermodynamic parameters 
derived from the ITC experiments indicated that these heterodimers formed spontaneously via an 
endothermic process. The heterodimers formed are smaller in mass than the homodimers, yet an 
increase in FP values occurred upon IpgC addition to IpaB’s N-terminal domain. The formation 
of a heterodimer may lend some structural rigidity to the N and C-termini of the IpaB fragments 
which is reflected in the FP values of the probes located at these sites. This structural rigidity 
would account for an increase in FP values despite formation of a product with a smaller 
molecular mass. What we may have observed was a decrease in the “propeller effect,”154 which 
refers to the artificially low FP values observed when a fluorescent molecule is linked to a highly 
flexible entity. Flexibility within the termini of these fragments is likely the reason that they were 
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not resolved in the crystal structure of IpaB
74-224
.
150
 We utilized FRET to determine if a 
conformational rearrangement occurred within the IpaB N-terminal domain upon binding to IpgC 
by taking advantage of the Cys residues placed at the N- and C-termini of IpaB
1-226
 and IpaB
28-226
. 
A dramatic increase in distance between W105 and the N-terminus of IpaB
N1-226
 was observed 
upon IpgC addition, indicating that IpaB may adopt a more extended conformation in the region 
containing CBS 1 following association with IpgC.  
Within the bacterial cytoplasm, IpaB remains bound to IpgC within a stable 
heterodimeric complex. The ATPase at the base of the T3SS provides the input of energy 
required to overcome the IpaB-IpgC interaction,
159
 perhaps through some conformational change 
in one or both proteins. The data in this chapter show that IpaB and IpgC form heterodimeric 
complexes and, as a result, IpaB undergoes a conformational change. This is an important 
observation that helps to explain a poorly understood step between the construction of the nascent 
T3SS and the recruitment of IpaB to the T3SS needle tip. 
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CHAPTER III 
 
 
INFLUENCE OF OLIGOMERIC STATE ON THE INTERACTION OF IPAB WITH 
PHOSPHOLIPID MEMBRANES 
 
Introduction 
Invasion plasmid antigen B (IpaB) is the first hydrophobic translocator protein secreted 
by the Shigella T3SS. Studies by our group have demonstrated that recombinant IpaB can exist in 
two distinct oligomeric states.
157
 Oligomeric IpaB is co-expressed with its cognate chaperone, 
IpgC to maintain IpaB in a soluble state.
91,144
 The translocator-chaperone complex is dissociated 
using either of the mild detergents N,N-dimethyldodecylamine N-oxide (LDAO) or n-octyl-oligo-
oxyethylene (OPOE).
144,157
 IpaB exists primarily as a monomer when prepared in LDAO, 
whereas it exists primarily as a tetramer when prepared in OPOE.
157
 Both oligomeric states of 
IpaB can interact with liposomes, however, only the tetrameric state is capable of forming pores 
in liposomes.
157
 Other groups have shown that higher-order IpaB oligomers induce pyropotosis in 
macrophages by forming cation-selective channels.
158
 IpaB has also been shown to activate the 
caspase-1 mediated apoptotic pathway.
79
 IpaB may be capable of existing in distinct oligomeric 
states depending on the stage of infection.
157 
 IpaB has a hydrophobic region stretching from approximately residue 310 to 420.
160
 This 
prediction is based on bioinformatic sequence analysis and has never been experimentally tested. 
To better understand the nature of IpaB’s interaction with host cell membranes, we introduced  
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several single Cys substitution mutations throughout the length of the protein. We then purified 
each of these point mutants in its monomeric or tetrameric state. The Cys residues allowed for 
site-specific labeling with the fluorescent probe fluorescein-maleimide (FM). The modified 
proteins were used in fluorescence quenching experiments to determine how the solvent 
accessibility of each residue was affected by the oligomeric state of IpaB and by membrane 
interaction. Our experiments provide evidence that the membrane-interacting domain of IpaB is 
larger than the predicted hydrophobic region, and suggest sequences outside of the hydrophobic 
region of IpaB are important for oligomer formation. Interestingly, we found that the hydrophobic 
domain was more exposed in the soluble tetrameric state, which is capable of pore formation after 
membrane association. The hydrophobic region was also the most protected from quenching 
following liposome interaction, suggesting that the hydrophobic region does, in fact, drive 
membrane interaction. We also found that residues outside of the hydrophobic region are 
involved in pore formation.  
We then sought to determine if there is a minimum part of IpaB’s hydrophobic domain 
required for membrane interaction or pore formation. Limited proteolysis was used to reveal 
structural differences between the monomer and tetramer, as well as their respective membrane-
associated states. We used the proteolytic products of IpaB in liposome flotation analysis and 
found that certain products were enriched in the liposome-containing fraction. Next, fragments 
with unique proteolytic termini were cloned, recombinantly expressed, and purified. These 
truncated forms of IpaB were evaluated for their ability to interact with and form pores in 
liposomes. We found that IpaB
11-495
 was capable of forming pores in model membranes in both its 
monomeric and tetrameric states, whereas full-length IpaB can only form pores as a tetramer. The 
observation that IpaB
11-495 
was capable of forming pores even when it was prepared as a monomer 
could indicate the C-terminal 85 residues regulate pore formation through an unknown 
mechanism. 
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Results  
Cys mutations do not abolish IpaB activity in vivo  
 IpaB contains a single native Cys at position 309. This residue was mutated to Ser, and 
the resulting ΔCys plasmid was used as the template for generating the other Cys mutations. We 
generated IpaB S58C, S107C, S149C, S237C, A254C, A353C, S486C, and S519C using inverse 
PCR. Plasmids containing the ipaB variants were transformed into the ipaB-null strain, SF620, to 
determine the in vivo impact of the ipaB mutations on Shigella in contact-mediated hemolysis, 
and invasion assays. Contact-mediated hemolysis was used to determine if the Cys mutations 
affected Shigella’s ability to insert a functional translocon pore into cells (Table 2.1). The Cys 
mutations did not negatively affect the hemolytic ability of Shigella beyond modest 15% and 17% 
decreases for IpaB S149C and S519C, respectively. We also performed gentamycin-protection 
assays to measure the ability for Shigella expressing IpaB Cys variants to invade cultured HeLa 
cells (Table 2.1). This assay is a more sensitive measure of protein function within the T3SS. 
IpaB S107C, S149C, A254C and A353C were approximately 50% less invasive than the positive 
control, which is still indicative of efficient entry into cultured cells. Because these proteins did 
not dramatically attenuate the virulence functions of Shigella, we were able to confidently 
continue with our studies. 
IpaB Cys mutants retain the previously described functions of the wild-type protein in vitro  
 We co-expressed IpaB S58C, S107C, S149C, S237C, A254C, A353C, S486C, and 
S519C, as well as the wild-type IpaB which contains a Cys at 309 in E. coli with IpgC. IpaB was 
then separated from IpgC using the mild detergents LDAO and OPOE, giving rise to a 
monomeric or tetrameric state of the protein, respectively. As an indicator of protein function, the 
capacity for IpaB to form pores in vitro was measured by a liposome disruption assay (Figure 
2.1). In this assay, defined liposomes containing 100 mM sulforhodamine-B (SRB) are prepared. 
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Table 2.1. Contact-Hemolysis and Invasion by Shigella Expressing ipaB variants.  
Shigella strain   Hemolysis
a
  Relative Invasion
b
 
SF620    3.2 ± 0.2  0.7 ± 0.6 
SF620 + WT ipaB  100 ± 11.8  100.0 ± 8.8 
SF620 + S58C    114.5 ± 4.0  88.7 ± 23.0 
SF620 + S107C   94.4 ± 1.9  43.3 ± 8.3 
SF620 + S149C   85.2 ± 3.4  43.5 ± 12.3 
SF620 + S237C   112.0 ± 4.0  93.3 ± 8.4 
SF620 + S254C   93.1 ± 8.3  52.4 ± 6.1 
SF620 + A353C  94.4 ± 5.2  45.7 ± 6.1 
SF620 + S486C   97.8 ± 1.8  80.8 ± 7.9 
SF620 + S519C   83.2 ± 3.4  103.1 ± 21.4   
a
Contact-mediated hemolysis using sheep red blood cells was performed to determine the impact 
of individual Cys mutations on IpaB’s ability to be delivered into target cell membranes by 
Shigella.
161
 
b
A gentamycin-protection assay using HeLa cells was performed to determine the 
impact of single Cys mutations on Shigella’s invasive capacity. The positive control was SF620 
transformed with native ipaB (100% relative invasion). The values shown are an average (n = 3) 
from a representative experiment ± standard deviation. WT = Wild-type. 
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Figure 2.1 Fluorophore release by IpaB Cys variants. Recombinant IpaB mutants were 
evaluated for their ability to cause release of SRB from liposomes as detailed in experimental 
procedures. Error bars represent standard deviations (n = 3). Tetrameric wild-type IpaB (WT) 
prepared in OPOE was used as a positive control and all values shown are relative to this level of 
SRB release. Addition of buffer alone (PBS) was used as a negative control.  
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Due to the high concentration of SRB within the liposomes, SRB is autoquenched. When SRB is 
released from the liposomes an increase in fluorescence emission signal is observed as the 
autoquenching is relieved.
162
 Previous studies demonstrated that the monomeric IpaB does not 
lead to a substantial release of SRB from liposomes, indicating that the monomeric protein is 
incapable of forming a pore. Tetrameric IpaB, on the other hand, is capable of forming pores and 
leads to a substantial release of fluorophore. Thus, we used this assay to evaluate the in vitro 
ability for the IpaB Cys variants to form pores in liposomes (Fig 2.1). We found that the 
monomeric IpaB Cys variants did not lead to substantial release of fluorophore, whereas the 
tetrameric form of each protein did promote pore formation. IpaB S58C had a reduced ability to 
form pores, which is interesting since this mutant was fully hemolytic when tested in vivo. The 
rest of the IpaB Cys variants were at least 60% as effective as the wild-type protein. Therefore, 
we were confident that the Cys mutations did not abrogate the in vitro function of IpaB.  
Impact of oligomerization on the accessibility of various regions of IpaB 
 Monomeric and tetrameric IpaB Cys variants were labeled with fluorescein-maleimide 
(FM) and used in fluorescence quenching experiments. Potassium iodide (KI) was used as the 
quenching agent. The resulting data were plotted using the Stern-Volmer equation and fit to a 
linear regression (Equation 3). The slope of the linear regression represents the Stern-Volmer 
quenching constant (KSV, Table 2.2). The KSV is a measure of the accessibility of a fluorophore to 
a quenching agent. To aid in data interpretation, we calculated a protection index (PI, Equation 4) 
for each position, in this case using the oligomeric state of IpaB as the variable (Figure 2.2). A PI 
= 1 indicates no change in the solvent accessibility of a particular residue, whereas a PI > 1 or PI 
< 1 indicates that the fluorophore was less available or more available for quenching relative to 
the variable condition, respectively.
163
 In Figure 2.2, residues 58 and 519 were the most protected 
positions in the tetramer relative to the monomeric state. This means that the KSV of the tetramer 
was lower than the KSV for the monomer, resulting in a numerical (PI) value > 1. The solvent 
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Table 2.2. KSV Values for the Quenching of IpaB by Iodide.     
       KSV      
    - Liposomes    + Liposomes   
Mutant   Monomer Tetramer  Monomer Tetramer  
S58C   6.68 ± 0.11 4.81 ± 0.02  6.62 ± 0.11 4.41 ± 0.02 
S107C   5.26 ± 0.19 5.21 ± 0.01  3.98 ± 0.04 3.94 ± 0.02 
S149C   7.26 ± 0.18 6.39 ± 0.09  6.22 ± 0.13 5.99 ± 0.07 
S237C   5.29 ± 0.06 4.63 ± 0.02  4.01 ± 0.05 4.16 ± 0.02 
A254C   7.07 ± 0.24 6.53 ± 0.16  5.66 ± 0.18 5.94 ± 0.13 
WT (309C)  4.91 ± 0.05 5.24 ± 0.11  3.96 ± 0.06 3.41 ± 0.04 
A353C   4.79 ± 0.02 7.08 ± 0.08  3.29 ± 0.02 3.97 ± 0.02 
S486C    5.23 ± 0.07  5.57 ± 0.03  4.62 ± 0.06 4.24 ± 0.02 
S519C   5.84 ± 0.04 4.82 ± 0.06  4.71 ± 0.04 4.28 ± 0.03  
Carboxyfluorescein (CF)  10.83 ± 0.42    10.69 ± 0.38   
100 nM FM-labeled IpaB was subjected to fluorescence quenching using KI as described in 
Experimental procedures. Shown here are representative KSV values with standard errors (n = 3). 
WT = wild-type. 
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Figure 2.2 Oligomeric state affects the accessibility of quenching agent to the hydrophobic 
region of IpaB. FM-IpaB (100 nM) prepared in LDAO (monomeric) and OPOE (oligomeric) 
was quenched by titration of KI in the absence of liposomes. The protection index (PI) for 
oligomer formation was calculated using KSV 
Mono
 / KSV 
Tet
 as described in Materials and Methods. 
Error bars represent standard deviation of the PI’s derived from at least three independent 
experiments performed in triplicate. Statistically significant differences are indicated by *, P < 
0.02 when tested against the native Cys (309) using the t test. 
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accessibility of residue 107 was unaffected by the change in oligomeric states, indicating that it 
exists in a similar environment in the monomer and tetramer. The data reflect relatively small 
increases in the protection of residues 149, 237, and 254 in the tetrameric form of IpaB relative to 
the monomer.  
 The most striking result here is the low PI value for residue 353. The low PI indicates that 
this residue was actually more exposed to solvent than in the monomeric state. This is surprising 
because residue 353 is located in the heart of the hydrophobic domain. The nearest residues, 309 
and 486, were also slightly less protected in the tetrameric form of IpaB. Residue 486 lies outside 
of the predicted hydrophobic region (residues 310-420). Taken together, these data may reveal 
protein-protein contacts important for IpaB’s organization as a tetramer are located outside of the 
hydrophobic region and that the hydrophobic region of IpaB is most exposed to solvent in the 
tetrameric complex. 
The hydrophobic domain is protected by liposome interaction.  
 Above it was shown that all of the IpaB Cys mutants interacted with liposomes in vitro 
and that the monomer and tetramer interact with liposomes in different ways, i.e. interaction vs. 
pore insertion (Figure 2.1). Therefore, we sought to determine the impact of liposome interaction 
on the accessibility of the FM probes conjugated to each of the IpaB Cys residues to the polar 
quenching agent KI (Figure 2.3). Each FM-IpaB variant was incubated with liposomes, and then 
KI was titrated into the samples to progressively quench the FM fluorescence. We used these data 
to calculate the KSV for each Cys position and then determined the PI caused by interaction with 
the liposomes (Equation 5). Carboxyfluorescein, a water-soluble fluorescein derivative, was used 
as a control for the impact of liposomes on the emission properties of fluorescein. 
 The KSV changes seen following liposome addition gave rise to an interesting observation 
for the FM at residue 353. This residue is within the hydrophobic domain of IpaB and was the 
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Figure 2.3 Protection of FM-labeled IpaB mutants from KI quenching by liposome 
association. Monomeric and oligomeric FM-IpaB (100 nM) was subjected to quenching in the 
absence or presence of liposomes composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC), 1,2-dioleoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)] (DOPG), and cholesterol. The 
protection index (PI) for liposome association was calculated using KSV
 –Lip
 / KSV
 +Lip
 for each FM-
labeled IpaB point mutant in both the monomeric (black bars) and tetrameric (shaded bars) states. 
Carboxyfluorescein (CF) was used as a control to demonstrate that the addition of liposomes does 
not arbitrarily affect the quenching of fully exposed fluorescein. Error bars represent standard 
deviation of the PI’s derived from three independent experiments performed in triplicate. 
Statistically significant differences between the monomer and tetramer for each IpaB variant are 
indicated by *, P < 0.05 using the t test. 
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most solvent exposed residue for the IpaB tetramer (Figure 2.2), however, it showed the greatest 
PI increase of all samples tested upon incubation with liposomes. Monomeric IpaB A353C also 
showed a substantial PI increase upon liposome addition, but not to the extent of that seen for the 
tetramer. Residue 309 and 486 were also significantly more protected by liposomes for the 
tetramers relative to the monomeric forms of IpaB. Collectively, the data suggest that residues 
309, 353, and 486 are involved in membrane penetration and this is especially clear for the IpaB 
tetramers.  
It is worth noting that residues 149, 237, 254, and 519 were more protected from 
quenching agent by liposomes for monomeric IpaB than for the tetramer. The significance of this 
observation is not clear, but it may reflect differences in the modes of liposome interaction of 
monomeric IpaB vs. tetrameric IpaB. IpaB S107C was not differentially protected depending on 
its oligomeric state, which agrees well with the protection by oligomerization PI = 1 (Figure 2.2), 
however, it was protected by liposome interaction. This residue lies within IpaB’s highly soluble 
N-terminal domain, so it would seem unlikely that this region of IpaB actually initiates membrane 
interaction and liposome flotation experiments with IpaB
28-226
 indicated that it does not interact 
with liposomes.
157
 Also, none of the nearby Cys residues were substantially protected from 
quenching by liposomes, supporting the notion that residue 107 is not driving membrane 
interaction. Residue 58 was not protected by liposomes, consistent with being in a highly soluble 
region of IpaB. 
Limited Proteolysis reveals structural differences between monomeric and tetrameric IpaB  
 We hypothesized that structural differences exist between monomeric and tetrameric 
IpaB, and that membrane interaction could cause changes in IpaB’s conformation. Samples 
containing wild-type monomeric and tetrameric IpaB were prepared in the presence or absence of 
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liposomes, after which the samples were exposed to subtilisin-A, a serine-protease, for a defined 
period of time.  
Monomeric IpaB was more resistant to proteolysis than tetrameric IpaB as indicated by 
the persistence of higher-mass products in Figure 2.4. Incubation with liposomes, however, led to 
rapid degradation of monomeric IpaB to a 40 kDa product and a pattern that was similar to that 
observed for tetrameric IpaB. This suggests that the protease cleavage sites are readily available 
in the membrane-inserted condition. Tetrameric IpaB was rapidly degraded to a 40-kDa product 
regardless of whether the liposomes were present, and this degradation was slightly expedited in 
the presence of liposomes. It is possible that LDAO impacts the activity of subtilisin-A. To 
address this, a T3SS protein that does not interact with liposomes, IpaD, was used as a control to 
determine if LDAO was impacting subtilisin-A activity (Figure 2.5). IpaD was degraded to a 
similar extent in the presence of LDAO or OPOE. Therefore, the detergents did not influence the 
proteolytic activity of subtilisin-A. 
Identification of IpaB fragments that retain liposome interaction activity  
 To better define what regions of IpaB interact with liposomes, we designed limited 
proteolysis experiments. Monomeric IpaB was digested with subtilisin-A and the reaction was 
stopped by adding the protease inhibitor AEBSF. The resulting IpaB peptides were incubated 
with liposomes that were then floated over a sucrose density gradient to isolate peptides able to 
interact with liposomes. After separation of the bottom and top fractions of the gradient, the 
proteins were concentrated by trichloroacetic acid precipitation. SDS-PAGE analysis of the 
precipitated proteins revealed three distinct bands of 40 kDa, 37 kDa, and 30 kDa that co-
migrated with the liposomes (Figure 2.6). These three bands were also found in the bottom of the 
gradient with an additional band at 25 kDa. Samples were submitted for mass spectrometric (MS) 
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Figure 2.4. Susceptibility of IpaB to proteolysis is influenced by oligomeric state and 
liposome interaction. Monomeric (A) or tetrameric (B) IpaB was subjected to proteolysis by 
subiltisin-A in the absence or presence of liposomes, as indicated above the gel images. Samples 
were analyzed on 12% SDS-PAGE gels. Time points (in seconds) are indicated above each lane 
in the gels. Gels were stained with Coomassie blue R250 and imaged on an Odyssey infrared 
imager (LI-COR, Lincoln, NE) to detect low-abundance products. 
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Figure 2.5. Limited proteolysis of IpaD. IpaD in (A) PBS + 0.05% LDAO or (B) PBS + 0.5% 
OPOE was diluted to 0.4 mg/ml. Subtilisin-A was added at a final dilution of 1:160,000 (relative 
to the subtilisin-A stock). Aliquots were removed from the digestion and placed into 99° C 3x 
SDS-PAGE sample buffer at the time points indicated below each lane. Samples were analyzed 
on 12% SDS-PAGE gels. Gels were stained with Coomassie blue R250 and imaged on an 
Odyssey infrared imager (LI-COR, Lincoln, NE) to detect low-abundance products. Molecular 
masses in kDa are indicated on the left. 
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Figure 2.6 Flotation following limited proteolysis of IpaB. IpaB was exposed to subtilisin-A 
for 30 seconds and placed on ice after the addition of 20 mM AEBSF. Top, middle, and bottom 
fractions were collected from the gradient. Fractions were analyzed by SDS-PAGE. The gel was 
stained with Oriole fluorescent gel stain (Biorad). The large, diffuse band at the bottom of the two 
leftmost wells is liposomes. Molecular mass is indicated on the left, in kDa. Small arrowhead = 
37 kDa band; thin arrowhead = 30 kDa band; large arrowhead = 25 kDa band.  
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analysis, which identified several IpaB peptides with unique cleavage sites. Unfortunately, there 
was overlap among the bands, which prevented confident identification of each band. The MS 
analysis, while not conclusive, did highlight peptides that warranted further investigation. Thus, 
we generated recombinant IpaB
11-312
, IpaB
11-357
, IpaB
11-390
, and IpaB
11-495
. The truncated proteins 
were used for co-expression with IpgC in E. coli Tuner (DE3) and all of them could be co-
expressed successfully with IpgC, except for IpaB
11-495
. To generate IpaB
11-495
, we introduced a 
tobacco etch virus (TEV) protease site into IpaB
11-580
 (IpaB
11-580
 
TEV 495
). The resulting gene was 
co-expressed with IpgC as before, purified, and then the IpaB
11-580 TEV 495
- IpgC complex was 
digested with TEV protease to generate an IpaB
11-495
-IpgC complex. The truncated forms of IpaB 
were purified as IpaB-IpgC complexes and were then separated from the chaperone using LDAO 
or OPOE, which for the full-length protein gives rise to monomeric and tetrameric states of IpaB, 
respectively. Both detergents were used separately to determine if the truncated proteins behaved 
differently in the two detergents. Each protein was analyzed by liposome flotation, and it was 
found that all of the proteins interacted with liposomes as indicated by their presence in the 
liposome-rich “top” fraction (Figure 2.7). IpaB11-312 had a reduced affinity for liposomes, which is 
likely because it lacks a substantial part of the hydrophobic region. IpaB
11-357
, IpaB
11-390
, and 
IpaB
11-495
 interacted with liposomes to an extent similar to that of wild-type IpaB.  
 The truncated forms of IpaB were next analyzed by chemical crosslinking to determine if 
they were capable of oligomer formation. The fluorescence quenching data presented above 
suggest that the termini of IpaB are implicated in IpaB oligomerization (Figure 2.2), so we used 
these truncated forms of IpaB to explore that possibility. Other in vivo studies have implicated the 
extreme C-terminus of IpaB in forming the interactions necessary to maintain IpaB on the needle 
tip.
164
 IpaB
11-312
 formed mostly monomers with and a minor population of dimers, whereas 
IpaB
11-357
 formed mostly dimers with a minor population of monomers in both LDAO and OPOE 
(Figure 2.8A). IpaB
11-390
 formed dimers and formed tetramers (Figure 2.8B). IpaB
11-495
 behaved 
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Figure 2.7 Floatation analysis of truncated forms of IpaB. Truncated forms of IpaB were used 
at a final concentration of 3 µM and were incubated with 4.4 mg/ml liposomes followed by 
separation on a sucrose density gradient. Top and bottom fractions were collected and analyzed 
by SDS-PAGE. Gels were stained with Oriole fluorescent gel dye (Biorad) and quantified by 
densitometry. Data are presented as averages of at least three independent experiments. Error bars 
represent standard deviations (n = 3). 
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Figure 2.8 Cross-linking of truncated forms of IpaB. IpaB
11-312
 and IpaB
11-357
 (Panel A),IpaB
11-
390
 (Panel B), and IpaB
11-495
 (Panel C) were separated from IpgC with either LDAO (L) or OPOE 
(O). 5 µM protein was cross-linked with DSP and separated on a 4-20% gel and stained with 
Oriole fluoresecent gel stain (Biorad). Molecular masses are indicated on the left hand side of 
each panel. 
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much like wild-type IpaB,
157
 where in LDAO it formed mostly monomers and in OPOE it formed 
mostly tetrameric complexes (Figure 2.8C). IpaB
11-495
 and IpaB
11-390
 in OPOE formed aggregates 
too large to enter the gel, but not when prepared in LDAO, perhaps reflective of the tendency for 
LDAO to prevent aggregation of IpaB.
157
 These data suggest that the C-terminal 85 residues are 
not necessary for oligomerization. Next the truncated forms of IpaB were evaluated for their 
capacity to form pores in liposomes (Figure 2.9). We found that IpaB
11-495
 promoted release of 
SRB, whereas the other truncated forms of IpaB did not. IpaB
11-312
 in OPOE may promote release 
of fluorophore, but this activity varies as indicated by the large error bars. We expected that 
tetrameric IpaB
11-495
 would form pores since full-length IpaB behaves in this way, however, we 
found that monomeric IpaB
11-495
 also released nearly 60% of the total fluorophore. Full-length, 
monomeric IpaB does not release substantial amounts of fluorophore. This could indicate that the 
C-terminal 85 residues of IpaB play a role in regulating pore formation.  
Incubation with liposomes imposes ordered oligomerization on IpaB 
 To determine if liposome interaction affected the oligomeric state of IpaB, monomeric or 
tetrameric IpaB
11-495 
and full-length IpaB were incubated with liposomes and cross-linked with 
the chemical cross-linking agent Bis[sulfosuccinimidyl] suberate (BS3). BS3 was chosen because 
it is polar and does not cross lipid membranes. When monomeric IpaB was cross-linked without 
liposomes, it remained mostly monomeric, with a small amount of dimer (Figure 2.10 A). When 
incubated with liposomes, the monomer transitioned to products with masses consistent with 
tetramers and octomers. These data suggest that monomeric IpaB is capable of self-organizing 
within a lipid membrane to form a higher-order oligomer.  
IpaB prepared in OPOE forms primarily tetramers when cross-linked with DSP.
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Oligomeric IpaB cross-linked with BS3 in the absence of liposomes, however, formed mostly 
tetramers and octomers, along with complexes too large to enter the gel. Interestingly, when 
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oligomeric IpaB was incubated with liposomes, it formed monomers, dimers, tetramers, and 
octomers. Only small amounts of immeasurable products were formed. These data suggest that 
liposome interaction maintains IpaB as a tetramer or octomer. However, the large proportion of 
monomer in the presence of liposomes suggests the possibility that liposome interaction may 
interfere with the cross-linking of the tetramer via steric shielding of reactive residues.  
IpaB
11-495
 behaved in a similar way to full-length IpaB. IpaB
11-495
 prepared with LDAO 
forms a monomer in solution, but when incubated with liposomes it forms a series of oligomers, 
some consistent with dimers, tetramers, and octomers (Figure 2.11). When prepared with OPOE, 
IpaB
11-495
 forms tetrameric complexes and higher-order aggregates. Oligomeric IpaB
11-495
 
becomes more ordered when incubated with liposomes, where it does not form a large number of 
higher ordered aggregates (Figure 2.11). 
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Figure 2.9 Liposome disruption experiments using the truncated forms of IpaB. 100 nM 
truncated forms of IpaB were added to liposomes containing 100 mM sulforhodamine-B (SRB). 
SRB release was monitored for 4 min, after which all dye was released by the addition of 0.1% 
Triton X-100. Percent release was calculated by dividing the fluorescence intensity after Triton 
addition by the fluorescence intensity immediately prior to Triton addition, multiplied by 100. 
Results presented are the average of at least three independent experiments (n = 3). Error bars 
indicate the standard deviation.  
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Figure 2.10 Impact of liposome association on the oligomeric state of IpaB. 5 µM monomeric 
(A) and tetrameric (B) were incubated for ten minutes with or without 7.0 mg/ml 
A 
B 
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Continued (Figure 2.10 legend) 
 
liposomes. Then the chemical cross-linking agent BS3 was added to a final concentration of 200 
µM. Samples were removed every five minutes and placed in 3x SDS-PAGE sample buffer to 
quench the reaction. Cross-linked products were separated on a 4-20% TGX gradient gel (Bio-
Rad). From left to right, the lanes represent samples taken at 0 (before cross-linking), 5, 10, 15, 
20, 25, and 30 min. The gel was stained with Oriole fluorescent gel stain (Biorad). Molecular 
masses are indicated by the ladder in the first or second lane of each gel in kDa. 
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Figure 2.11. Cross-linking IpaB
11-495 
reveals similarities to full-length IpaB. IpaB
11-495 
prepared in either 0.05% LDAO or 0.5% OPOE was incubated in the absence or presence of 
liposomes and then cross-linked with BS3. Cross-linked products were separated on a 4-20% 
TGX gradient gel (Bio-Rad). The time points are indicated across the bottom of the gel. 
Molecular masses (in kDa) are indicated on the left. – Lip = no liposomes; + Lip = + liposomes.  
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Conclusions 
 The data presented in this chapter illuminated some aspects of IpaB’s interaction with 
itself and with lipid membranes. The quenching data suggested that the oligomeric state affects 
the extent to which residues within the hydrophobic domain interact with membranes. The 
hydrophobic domain is critical to protein structure because deleting nearly any part of this region 
leads to loss of invasion function.
160
 Quenching and proteolytic data suggest that IpaB regions in 
addition to the described hydrophobic domain are involved with membrane interactions. C-
terminally truncated forms of IpaB also suggested a novel role for the C-terminal 85 residues in 
controlling pore function. Collectively, these data were used to provide an updated model of 
IpaB’s interaction with itself and with membranes (Figure 2.12). 
 The hydrophobic domain is more solvent exposed upon IpaB oligomerization than it is 
for the monomer, whereas the termini are less exposed. This suggested that IpaB oligomerization 
could be due to specific protein-protein interactions within the hydrophilic termini instead of 
nonspecific hydrophobic collapse. However, we found that IpaB
11-495 
could oligomerize in OPOE, 
suggesting that the C-terminal 85 residues are dispensable for oligomer formation. The relative 
size of the full-length IpaB tetrameric complex and ability to form pores is consistent with this 
complex being the one observed at the T3SS needle tip. IpaD is a pentamer at the T3SS needle 
tip
165
 and it is predicted that an IpaB tetramer would fit on top of the IpaD pentamer based on 
computations that account for molecular mass and the predicted structure of IpaB (Epler, C.R. 
and Bullit, E., unpublished observations). This is speculative and this hypothesis is currently 
being tested. The experimental data here lead one to speculate that exposure of a hydrophobic 
region to solvent, an energetically unfavorable event, may occur at the T3SS needle tip in 
preparation for host cell contact. This is further supported because the increased solvent 
accessibility of the hydrophobic region is lost upon liposome interaction. Collectively, these data 
suggest that the hydrophobic domain plays a central role in IpaB translocon pore formation. 
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Figure 2.12. Functional organization of IpaB with regard to oligomerization, chaperone 
binding and membrane association. (A) IpaB is shown as a single bar with regions believed to 
be involved in specific macromolecular interactions. Residue numbers (100, 200, etc.) are 
indicated above the bar. Chaperone-binding domains (CBD’s) based on experiments performed 
using a soluble IpaB fragment are indicated near the N-terminus. This region and sequences near 
the C-terminus may also be involved in protein-protein contacts (large arrows). A coiled-coil 
domain for which a crystal structure has been solved is also located in the N-terminal half of 
IpaB. Less is known about the structure of the C-terminal half of IpaB which contains a 
prominent hydrophobic region. It is in this region that IpaB may possess a hydrophobic α-helical 
hairpin (indicated) similar to what has been observed in colicins. (B) A closer look at the possible 
position of monomeric (left) and tetrameric (right) IpaB within the eukaryotic membrane. 
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Continued (Figure 2.12 legend) 
 
Initial contact may occur via the immediate region surrounding residue 353 with the oligomeric 
arrangement of the protein then allowing a more intimate interaction with the hydrophobic core of 
the membrane.  
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The recent crystal structure of IpaB
74-224
 indicates that the N-terminal domain of IpaB is a 
long coiled-coil and a similar finding was made for the IpaB homolog from Salmonella, SipB 
residues 82-226.
150
 When queried against a structural homology search engine, both IpaB’s and 
SipB’s N-terminal domain shared a high degree of structural homology with the corresponding 
coiled-coil region of colicin Ia, a bacterial pore-forming toxin.
150
 Upon further analysis, it was 
found that regions within the highly-conserved hydrophobic domains
160,166
 of each protein, 
residues 310-370 of IpaB and 320-380 of SipB, shared sequence homology with an α-helical 
hairpin in the pore-forming domain of colicin Ia. The α-helical hairpin serves to anchor colicin Ia 
in the target membrane.
167
 IpaB residue 353 lies within the predicted α-helical hairpin motif. 
Residue 353 was the most protected residue by liposome interaction for both the monomeric and 
tetrameric states. Residues 309 and 486 also appeared to be important for pore formation. Similar 
to IpaB, colicin Ia oligomerizes prior to forming a pore.
168
 One could speculate that the α-helical 
hairpin plays a similar role in IpaB, which is supported by the high PI of IpaB A353C. The 
similarities between IpaB and colicin Ia are striking.  
Limited proteolysis was used because the quenching experiments suggested structural 
differences between the monomer and tetramer. Structural differences between the two states 
were supported by the proteolysis data. Surprisingly, the tetramer was more sensitive to 
proteolytic degradation than the monomer. The monomer may adopt a more compact structure 
that protects the hydrophobic region, rendering it less susceptible to proteolysis. In contrast, the 
proteolytic pattern of the monomer was substantially altered after incubation with liposomes. The 
proteolytic pattern of tetrameric IpaB was not significantly impacted by liposome interaction, 
suggesting that the subtilisin recognition sites are not masked by liposomes and no 
conformational change was detectable.  
 To further define what parts of IpaB interact with liposomes, we generated the following 
truncated forms of IpaB: IpaB
11-312
, IpaB
11-357
, IpaB
11-390
 and IpaB
11-495
. All of these proteins 
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interacted with liposomes, however, the protein with the smallest portion of the hydrophobic 
domain, IpaB
11-312
, had a decreased ability to do so. IpaB
11-390
 and IpaB
11-495
 were capable of 
forming oligomeric species when prepared in OPOE. Cross-linking analysis revealed that IpaB
11-
495
 in LDAO or OPOE formed almost exclusively monomers or tetramers, respectively. 
Interestingly, IpaB
11-495
 formed pores even when prepared as a monomer, which is attributable to 
the formation of oligomers when incubated with liposomes. This stands in contrast to monomeric 
full-length IpaB, which forms oligomers in liposomes, but is unable to form functional pores. 
This suggests that the cross-linking could be an artifact of locally higher protein concentration 
caused by localization of proteins to the liposome surface. If this were the case, however, one 
would expect the rapid formation of aggregates instead of discrete species. We also observed that 
IpaB prepared in OPOE formed discrete tetramers and octomers in liposomes without the 
formation of higher-order aggregates. This may be due to a slight conformational change, or 
conformational flexibility, that is required for IpaB to insert into liposomes.
157
 The resulting 
membrane- inserted tetramer/octomer may be impermissive to formation of higher-order 
structures, thus explaining the absence of higher-order aggregates from our data.  
The question remains as to why monomeric IpaB
11-495
 forms a pore and full-length IpaB 
does not, yet both proteins form higher-order oligomers when incubated with liposomes. The C-
terminal 85 residues of IpaB appear to be important in the control of pore function. Without these 
residues, IpaB
11-495
 generally behaves as full-length IpaB, except for this pore-forming 
phenomenon. These 85 residues are important for stable recombinant IpaB expression, since we 
had to generate this protein by inserting a TEV protease site and specifically cleaving the final 85 
residues from IpaB.  
As a whole, the data presented here suggest that regions in addition to the hydrophobic 
domain of IpaB are involved in membrane association and that the C-terminal domain plays a 
role in controlling IpaB’s pore forming function. The quenching data suggest that residues 309, 
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353 and 486 contribute to pore formation. They also indicated that the region surrounding residue 
353, a predicted α-helical hairpin, plays a central role in membrane interaction. Deletion of the 
entire C-terminal region (residues 410-580) of IpaB partially attenuates the invasion function of 
Shigella, and eliminates the ability to bind to caspase-1.
160
 We found that the C-terminal 85 
residues of IpaB may have a role in controlling pore function, and are not required for oligomer 
formation. IpaB
28-226
 does not interact with liposomes, so the N-terminal boundary of the 
membrane-interaction domain is somewhere between residues 226 and 309. IpaB
28-226
 was 
identified as a stable proteolytic product (see Ch. I) which suggests that residue 226 is near a 
boundary between the two more structured regions. The quenching data suggest that the region 
encompassing 237 and 254 may play a role in peripheral membrane interaction, especially for 
monomeric IpaB. Others have shown that deletion of 247-277 abrogates IpaB function in 
Shigella,
160
 so this region may possess some under-appreciated function. Collectively these data 
suggest that the entire hydrophobic domain is required for pore formation but not for simple 
liposome interaction. It will next be important to determine the relationship between the structural 
forms we observe for recombinant IpaB and the IpaB complex that exists at the tip of the type III 
secretion of S. flexneri in vivo.  
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CHAPTER IV 
 
 
SIDE PROJECTS 
 
Pore-forming Harpins of the Type III Secretion System of Pseudomonas syringae  
Introduction 
Pseudomonas syringae is a Gram-negative plant pathogen that, like Shigella, uses a T3SS 
to deliver host-altering effector proteins into target eukaryotic cells.
169
 P. syringae consists of 
many pathovars specific to particular plant species, and can destroy crops such as tomatoes and 
soybeans.
169
 Secretion of effector proteins via the T3SS is required for P. syringae to infect and 
grow in plants.
170
 P. syringae is an important model organism because it is easily genetically 
manipulated with a fully sequenced and well-annotated genome.
169,171
  
Harpins are a class of T3SS effectors that are unique to plant pathogens and are thought 
to contribute to the translocation of T3SS effectors.
172
 The hypersensitive response (HR) and 
pathogenicity (Hrp)
169
 and Hrp outer proteins (Hop) are so named because they are translocated 
by the hrp/hrc (hypersensitive response and pathogencity/conserved) T3SS.
173
 The HR is a type 
of programmed cell death that occurs in plants in response to infection and injury.
172
 Harpins also 
invoke the HR.
172
 HrpZ1 and HrpW1 are harpins secreted by P. syringae, and are conserved 
across several pathovars.
174-176
 HrpZ1 is a lipid-binding and pore-forming protein.
177
 HrpW1  
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consists of a harpin domain and a putative pectate lyase domain within the N- and C-terminal 
halves of the protein, respectively.
172,174
 Additional harpins were recently identified and named 
HrpK1 and HopAK1.
172
 Like other harpins, HrpK1 and HopAK1 are capable of inducing the 
HR.
172
 When all four harpin genes are knocked out, P. syringae is unable to translocate bacterial 
effectors into plant cells, but it still secretes proteins into the medium.
172
 In the quadruple 
knockout strain, each of these harpins is capable of restoring the translocation function of the 
T3SS.
172
  
HopP1 is a lytic transglycosylase that is translocated into plant cells by the hrp/hrc 
T3SS.
178
 Lytic transglycoslyases are thought to degrade the peptidoglycan layer of Gram-negative 
pathogens in a controlled fashion to allow the deployment of extracellular appendages, such as 
those of T3SSs.
179
 HopP1 has recently been demonstrated to play a role in suppressing PAMP-
triggered immunity (PTI) of plants.
179
 Suppression of PTI is a necessary first step in evading the 
HR response, thus promoting pathogenesis.
179
 We evaluated the aforementioned Hrp and Hop 
proteins for their ability to form pores in liposomes.  
Results and Conclusions 
Using a fluorophore release assay,
144
 we evaluated the harpins for their ability to form 
pores in liposome vesicles (Figure 3.1). The liposomes consisted of 20% DOPG and 80% DOPC 
and contained 100 mM sulforhodamine-B (SRB). The Shigella proteins IpaB and IpaD were used 
as positive and negative controls, respectively. HrpK1 released 32% of the total SRB, and HrpZ1 
released 55%, indicating that HrpK1 and HrpZ1 were able to disrupt the liposomes. HopP1 
promoted the release of more SRB than did the negative control, however HopP1 was not 
particularly efficient in SRB release. HopAK1 and HrpW1 did not promote a significant amount 
of SRB release (only about 5% each).  
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HrpW1, HopP1, and HopAK1 each contain a putative pectin lyase domain and a harpin 
domain.
172,174
 Thus, these proteins are probably not translocator proteins since they were unable to 
complement a translocation deficient strain of P. syringae.
172
 While HrpW1, HopP1, and 
HopAK1 do not appear to be important for lipid bilayer penetration, as secreted effectors they 
may serve to degrade the plant cell wall to allow the T3SS to gain access to the cell membrane 
where the translocator proteins HrpK1 and HrpZ1 would be capable of forming the translocon 
pore. It has also been speculated that HrpW1 and HopAK1 could serve as a scaffold at the T3SA 
needle tip for the assembly of the translocon complex, much like the low-calcium response 
protein V (LcrV) in Yersinia
172
 or IpaD in Shigella.
180
 Recent findings suggest that HopP1 is a 
lytic transglycosylase that assists in the assembly of the T3SS machinery by enlarging the pores 
in the peptidoglycan layer of Gram-negative bacteria to allow the machinery to protrude from the 
cell.
178
 
HrpK1 and HrpZ1 have been shown to be necessary for the translocation of T3SS 
effector proteins, but not for secretion.
172
 A role in translocation is supported by our data which 
suggest that both HrpK1 and HrpZ1 form pores in phospholipid membranes. These proteins 
promoted the release of SRB from liposomes, but at a level lower than the positive control 
protein, IpaB. This could be because the Hrp’s are optimized for plant pathogenesis where they 
must span the cell wall in addition to the plasma membrane of plants, whereas IpaB only needs to 
span a single lipid bilayer to infect mammalian cells.  
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Figure 3.1. Evaluation of the liposome-disrupting capacity of P. syringae T3SS translocator 
candidates. See materials and methods for assay details. Tetrameric IpaB (prepared in the 
detergent OPOE) was used as a positive control for liposome disruption and IpaD was used as a 
negative control. Each bar represents the average of three independent experiments. Error bars 
represent the standard deviation (n=3) of at least three independent measurements. 
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Evaluation of the bacterial lytic capacity of P60-domain containing enzymes from 
Mycobacterium avium subsp. paratuberculosis K-10 
Introduction 
Mycobacterium avium subspecies paratuberculosis (MAP) is the etiologic agent of 
Johne’s disease in animals of agricultural significance, such as goats and cattle.181 Johne’s disease 
is a chronic enteritis that leads to malnourishment of the affected animals and can have a severe 
economic impact on the farm industry.
182,183
 MAP1204 and MAP1272c are major, surface-
exposed antigens of this bacterium and both contain a P60 domain and a membrane-anchoring 
domain.
181
 P60 domains impart enzymatic activity to their constituent proteins, including the 
ability to hydrolyze peptidoglycan.
181,184
 The function of prokaryotic P60 domains may be to 
modify the cell wall of bacteria to allow the extension of extracellular appendages.
181
 MAP1272c 
is poorly conserved across Mycobacterium species, and the protein encoded by the strain used in 
this study lacks a catalytic residue and is not expected to be enzymatically active.
181
 Thus, 
MAP1272c was used as a negative control in this study. Other MAP strains possess a form of 
MAP1272c with a putative Cys-His-His catalytic triad.
184
 MAP1272c may be erroneously 
annotated in the genomes of other MAP strains.
181
 The physiological role played by an inactive 
peptidase is unclear. 
To determine if MAP1204 enzymatically degraded peptidoglycan, its impact on the 
survival of the Gram-positive bacterium Bacillus subtilis was evaluated. MAP1204 is 
hypothesized to have a Cys-His-His catalytic triad similar to that proposed for other permutations 
of MAP1272c.
184
 Thus, a Cys to Ser mutation (MAP1204 C155S) of the predicted catalytic 
residue was generated. Understanding the function of MAP1204 and MAP1272c may lead to the 
development of novel therapeutic compounds that could interfere with the deployment of 
bacterial extracellular appendages.  
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Results and Conclusions 
Bacterial survival assays were employed to determine if the putative enzymes from MAP 
were capable of degrading peptidoglycan. Degradation of the peptidoglycan layer should lead to a 
decrease in bacterial survival. A laboratory strain of B. subtilis was selected for use in the 
bacterial survival assays as a representative Gram-positive organism. B. subtilis was incubated 
with increasing concentrations of the predicted peptidases (Figure 3.2). The bacteria were diluted 
in 0.1x PBS prior to the addition of MAP enzymes. In this case, the use of a hypotonic solution 
was necessary to observe a reduction in survival, perhaps because isotonic PBS did not force the 
exposed cytoplasmic membrane to rupture. As expected, MAP1272c was unable to reduce 
bacterial survival (Figure 3.2). This protein is catalytically inactive because it contains an alanine 
residue at the catalytic position. Incubating B. subtilis with MAP1204 reduced bacterial survival 
in a dose-dependent fashion (Figure 3.2). MAP1204 C155S reduced bacterial survival, though 
less efficiently, indicating that the mutation affected the ability for the enzyme to hydrolyze 
peptidoglycan but did not completely abrogate it. This mutation was not predicted to alter the 
structure of the protein, so the decreased activity was not likely due to protein unfolding. Ser-His-
His triads are common, and possess a similar relative orientation to the novel Cys-His-His.
184
  It 
is possible that since the predicted Cys-His-His catalytic triad is a novel active site arrangement, 
that it is relatively uncommon and may not compose the active site of MAP1204. Alternatively, 
C155S may be a tolerable mutation because Ser-His-His catalytic triads possess a similar relative 
orientation to Cys-containing triads.
184
 Whether or not this is the active site of the enzyme cannot 
be determined from the data presented here. 
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Figure 3.2. Impact of co-incubation of suspected peptidases from Mycobacterium avium 
subsp. paratuberculosis K-10 on the survival of B. subtilis. B. subtilis was incubated for one hr. 
in the presence of Hen egg white lysozyme (HEWL), MAP1204, MAP1204 C155S, or 
MAP1272c, plated onto LB agar plates and incubated overnight at 37° C. HEWL was used as a 
positive control, and is not shown here because B. subtilis survival was always 0% for this 
enzyme. Percent survival was normalized to the “no enzyme” condition for each series. Error bars 
represent the standard deviation of at least four independent experiments. Squares = MAP1204 
WT; circles = MAP1204 C155S; triangles = MAP1272c. 
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The Effect of Bile Salts on the Invasive Capacity of Salmonella enterica serovar 
Typhimurium 
Introduction 
Salmonella enterica serovar Typhimurium (S. Typhimurium) causes diarrheal disease in 
humans and livestock worldwide.
185
 This pathogen is transmitted via the fecal-oral route. S. 
enterica servars Typhimurium, Typhi, and Enteritidis have been shown to form chronic carrier 
states in humans through the establishment of biofilms on gallstones.
186
 Salmonella uses two 
different T3SSs encoded by two separate genetic islands depending on the stage of infection.
187
 
T3SS-1 is required for initial invasion of host tissues and is encoded by Salmonella pathogenicity 
island 1 (SPI-1). A SPI-2 encoded T3SS then mediates intracellular survival of the bacterium.
188
 
After invasion, Salmonella can disseminate systemically following invasion of macrophages and 
uses SPI-2 to maintain the bacteria-containing vacuole.
189
  
Bile consists of several detergents that help in the digestion of fats. Like other detergents, 
bile can damage bacterial cell membranes, however, enteric bacteria possess a variety of 
mechanisms that minimize the impact of bile on the cell membrane.
190
 In fact, some enteric 
pathogens use bile as an environmental signal.
83,190
 Salmonella encounters high concentrations of 
bile in the intestines of humans, however, it has been shown that overnight growth in 3% bile 
almost completely represses the invasive capacity of Salmonella because of repression of SPI-1 
gene expression.
191
 It was shown that incubation with 3% bile for as little as 30 min reduced the 
transcription of invasion genes.
192
 The aforementioned study, however, did not determine the 
impact of shorter incubation times on bacterial invasion. Thus, we sought to more closely 
examine the effect of bile on Salmonella invasion. 
Results and Conclusions 
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S. Typhimurium SB241 is isogenic to SL1344, except that SB241 is null for the T3SS 
effector protein SipD.
193
 SipD is essential for the invasion function of Salmonella.
193
 We grew 
SL1344 in LB + 3% oxgall, a desiccated bovine bile preparation. We exposed SL1344 to oxgall 
for 15, 30 or 60 min. during normal growth. It had been shown previously that bile eliminates the 
ability for Salmonella to invade cultured cells when exposed overnight.
191
 On the other hand, the 
bile salt deoxycholate (DOC) primes the T3SS by recruiting IpaB to the T3SS needle tip and 
thereby enhances the invasion of intestinal cells by Shigella.
83,194
  
The results of the gentamycin-protection assay are shown in Figure 3.3. SB241 was non-
invasive, as expected. SL1344 were grown in the presence of 3% oxgall for 15, 30 or 60 min 
prior to incubation with HeLa cells. The reduction in invasiveness was not statistically different 
among the time points, but invasion was decreased by ~50% relative to the control grown without 
3% oxgall (Figure 3.3). The OD600 of each culture was closely monitored, and thus these data are 
not reflective of a difference in multiplicity of infection. 
 These data reflect a ~50% decrease in invasiveness. Previous studies demonstrated that 
overnight growth in 3% oxgall completely inhibits the invasion function of Salmonella through 
transcriptional regulation.
192
 It has been shown that bile represses the expression of genes in the 
invasion pathway in as little as 30 min, but that study did not test the impact of bile on 
invasiveness at this time point.
192
 It is possible that the decreased invasion observed here was also 
due to transcriptional regulation, though it is unlikely that preexisting virulence machinery was 
degraded within this time period. These data suggest that it may take some time for the invasion 
function to be completely turned-off, perhaps due to the cytoplasmic pool of effector proteins that 
is hypothesized to accumulate in enteric pathogens.
72
 Thus, the selected time points were such 
that the SPI-1 T3SS may be transcriptionally deactivated, but the cytoplasmic pool of effector 
proteins
72
 was still available for secretion and therefore allowed invasion.  
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Figure 3.3 Standard gentamycin-protection assay using S. Typhimurium in the presence of 
3% oxgall. S. Typhimurium SL1344 was grown in the presence of 3% oxgall for the indicated 
times prior to incubation with semi-confluent HeLa cells. S. Typhimurium SB241, a strain 
lacking the T3SS effector SipD, was used as a negative control. Error bars represent standard 
deviation of three independent experiments.  
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Impact of inserting of a tetracysteine-pocket into IpaD  
Introduction 
Invasion plasmid antigen D (IpaD) is the secretion-controlling tip protein of Shigella’s 
T3SS.
180
 IpaD also serves as an environmental sensor by binding to bile salts.
83
 Multiple crystal 
structures for this highly soluble, 37 kDa protein have been published.
195,196
 Structural analysis 
reveals a long, central coiled-coil domain with two globular domains at either end of the coiled-
coil, resembling a dumbbell.
195
 The DOC binding site on IpaD is located at the interface of 
helices α3 and α7, as determined by a crystal structure of IpaD in complex with DOC.196 This 
observation agrees reasonably well with the previously established distance between the DOC 
binding site and the C-terminus of IpaD.
83
 IpaD contains two distinct, independently folding 
domains. The N-terminal 120 residues comprise a domain that serves as a self-chaperone for 
IpaD.
197
 The remainder of the protein is required for controlling type III secretion, especially 
what is termed the “distal domain.”165 Binding to bile salts induces a conformational change in 
IpaD,
198
 leading to IpaB docking on the T3SS needle tip.
84
 Growth in the presence of bile salts 
also causes Shigella to become about four times more invasive.
194
 This section will briefly discuss 
contributions made to a project exploring the subtle conformational changes that occur in IpaD 
upon binding to the bile salt deoxycholate (DOC).
198
  
Results and Conclusions 
Tertiary structure analysis of IpaD containing tetracysteine pockets 
Recombinant IpaD constructs were made to contain tetracysteine (TC) pockets (residues 
CCGPCC) that are specifically recognized by a fluorescin deriviative, 4′,5′-bis(1,3,2,-
dithioarsolan-2-yl) fluorescein (FlAsH-EDT2; Molecular Probes, Eugene, OR) for site-specific 
labeling.
198
 The TC pockets were inserted into unstructured regions of IpaD.
198
 Prior to 
performing the planned in vitro assays using these mutant proteins, they were tested for structural 
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defects using intrinsic tryptophan fluorescence. Trp is an environmentally-sensitive fluorophore 
that undergoes a blue-shift upon entering a more hydrophobic environment or a red-shift upon 
entering a hydrophilic environment.
154
 Therefore, Trp fluorescence is useful as an indicator of 
protein folding. IpaD contains four Trp residues, so this technique cannot supply information 
about the environment of a single a Trp, however, changes in protein structure or aggregation 
state are reflected by altered peak emission wavelengths.  
TC pockets were introduced into IpaD following residues 68, 184, 231, and 264 (TC68, 
TC184, TC231, and TC264, respectively). Wild-type IpaD (WT-IpaD) and TC-containing IpaD 
mutants TC68, TC184, TC231, and TC264 were purified as previously described.
199
 It was found 
that the tertiary structure of IpaD was not greatly impacted by the addition of TC pockets (Figure 
3.4). WT-IpaD and the TC pocket containing proteins had similar transition temperatures near 
65°C, defined as the midpoint of the transitions seen in Figure 3.4. TC184 had the most dramatic 
red-shift at the end of the experiment, finishing at 346 nm. TC231 has a transition midpoint of 
65°C and demonstrated a more intense red-shift at 65 and 72.5° C than the other proteins, and the 
final peak wavelength was 3 nm longer than WT-IpaD (345 nm vs 342 nm). TC264 followed a 
trend similar to TC231, but the final peak wavelength was only 1 nm longer than WT-IpaD. 
Interestingly, TC231 and TC264 were both located in the distal domain. One could speculate that 
these slightly red-shifted data points indicate a structural perturbation in these proteins, however, 
due to the very similar transition temperatures it is unlikely that any major tertiary structural 
changes occurred as a result of TC-pocket insertion. These proteins were used in downstream 
experiments at room temperature, and the peak emission wavelengths were very similar across 
10-40°C. Therefore, the addition of TC pockets to IpaD did not alter the tertiary structure. 
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Figure 3.4. Thermal stability of the tertiary structure of IpaD tetracysteine (TC) pocket-
containing mutants. Wild-type IpaD (squares), IpaD TC68 (upward triangles), IpaD TC184 
(circles), IpaD TC231 (downward triangles), and IpaD TC264 (diamonds) were excited at 295 nm 
and monitored for changes in peak emission wavelength as a function of temperature. The Y-axis 
is the peak emission wavelength in nanometers, the X-axis is the temperature in degrees C.  
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CHAPTER V 
 
 
DISCUSSION 
 
The purpose of this work was to examine the protein-protein and protein-lipid 
interactions that IpaB participates in within the T3SS. This study encompassed mostly in vitro 
biochemical approaches, including: fluorescence spectroscopy, chemical cross-linking, 
mutagenesis, and limited proteolysis. Data from this work contributed to the growing body of 
knowledge on the enigmatic and multifaceted role of IpaB. 
 Recombinant expression of IpaB requires IpgC.
144
 The major hurdle to investigating the 
IpaB-IpgC interaction is that the continued presence of detergents is required to maintain IpaB’s 
solubility.
144
 The detergents also prevent the reassembly of the translocator-chaperone complex 
(P. R. Adam, unpublished results). Our collaborator Dr. Brian Geisbrecht and his former student 
Dr. Michael Barta solved a partial crystal structure of IpaB, spanning residues 74-224 of the 580-
residue protein.
150
 They identified the soluble N-terminal domain of IpaB, which was used for 
further study. The N-terminus of IpaB has been shown to contain two separate chaperone binding 
sites (CBS) and the secretion signal.
149,200
 IpaB’s crystal structure was highly homologous to an 
extended coiled-coil in colicin Ia, a pore-forming toxin.
150
 The same study identified a predicted 
α-helical hairpin motif spanning residues 310-370 within the hydrophobic domain of IpaB.150 An 
α-helical hairpin motif in colicin Ia serves as a membrane anchor.152 Our laboratory was the first  
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to examine the structural consequences of the interaction between IpaB and the chaperone, 
IpgC.
151
  
  Studies with the soluble N-terminal domain were first directed at determining if it could 
in fact interact with IpgC. Fluorescence polarization, isothermal titration calorimetry, and cross-
linking data strongly suggested that the N-terminal domain does interact with IpgC.
151
 Further, 
the data supported the proposal by others that two separate CBS’s exist within the N-terminal 75 
residues.
151
 The data showed that IpaB undergoes a conformational change upon binding to 
IpgC.
151
 The exact nature of this conformational change remains unclear, but appears to affect 
regions of IpaB well outside of the CBS.
151
 A possibility is that the N-terminal domain of IpaB 
adopts a more elongated structure upon binding to IpgC.
151
 IpgC prevents IpaB from associating 
with phospholipid membranes
144,157
 and thus, IpgC may hold IpaB in a conformation that does not 
permit membrane interaction. Later work by our lab revealed that IpaB (without IpgC) requires 
structural flexibility to insert into liposomes.
157
 Thus, IpgC binding prevents IpaB from inserting 
into membranes due to a conformational change in IpaB, a lack of structural flexibility, or a 
combination of these factors.  
 The next series of experiments explored the nature of the IpaB-membrane interaction by 
probing the microenvironment of several residues within full-length IpaB. The Picking lab has 
previously reported that IpaB can exist as either a monomer or a tetramer, depending on the 
detergent used to separate IpaB from IpgC after recombinant expression.
157
 Furthermore, both of 
these oligomeric states are capable of interacting with lipid membranes, but differ in one key 
feature: tetrameric IpaB forms pores in lipid membranes, whereas monomeric IpaB does not.
157
  
 The hydrophobic domain was predicted to span residues 310-420.
160
 Guichon et al. found 
that deleting short segments (307-316, and 410-419) within the predicted transmembrane helices 
of IpaB resulted in an invasion-null phenotype in Shigella.
160
 Using both monomeric and 
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oligomeric IpaB, fluorescence quenching was used to examine how the surface topography of 
IpaB differed with regard to oligomeric state. The hydrophobic domain of tetrameric IpaB was 
much more solvent-exposed relative to the monomer. The hydrophobic domain was the most 
protected by membrane interaction, independent of oligomeric state. The data suggest that the 
pore-forming domain of IpaB may extend as far as residue 486, well beyond the predicted 
segment. Other studies have predicted that a tetramer of IpaB is recruited to the T3SS needle tip 
after exposure to bile salts.
165
 The recombinant IpaB tetramer may be structurally similar to the 
arrangement of the putative IpaB tetramer at the T3SS needle tip, although detailed structural 
analysis is needed to confirm this. Perhaps most importantly, the α-helical motif within IpaB 
appears to drive membrane interaction. The α-helical motif in IpaB thus represents an attractive 
target for novel antimicrobials and clearly warrants further study. 
 We next explored how large C-terminal truncations affected IpaB’s ability to interact 
with liposomes. Previous work found that deletions of residues 311-580 and 401-580 eliminated 
and reduced the invasiveness of Shigella, respectively.
160
 We found that very little of the 
predicted hydrophobic domain is needed for membrane interaction, because IpaB
11-312
 interacted 
with liposomes. However, complete absence of the hydrophobic domain (IpaB
28-226
) precludes 
membrane interaction.
157
 Of the truncated forms of IpaB, the most fascinating protein was 
IpaB
11-495
. This protein preserved almost all of the characteristics of the full-length protein, with 
one major difference. IpaB
11-495
 formed pores in liposomes when prepared as a monomer in 
solution. Therefore, since all previous data suggested that pore formation by IpaB depended on 
the oligomeric state, we explored if IpaB
11-495
 formed oligomers after it was introduced to 
liposomes. We found that full-length IpaB and IpaB
11-495
, when prepared as monomers, formed 
tetramers after incubation with liposomes. This suggests that the C-terminal 85 residues of IpaB 
play a role in the regulation of pore-formation.  
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The presence of a C-terminal peptide, IpaB
418-580
, prevents Shigella from invading 
cells.
166
 A similar observation was made for the IpaB homolog from Salmonella, SipB.
201
 More 
recently, it was shown that the deletion of as few as three residues from IpaB’s C-terminus can 
disrupt the ability of IpaB to associate with the T3SS needle tip.
164
 From our data and other 
studies, it is clear that the C-terminal residues of IpaB are functionally diverse and important. 
These residues appear to be necessary for regulating pore formation in vitro, and may be 
structurally important.  
 This work studied several aspects of IpaB and provided the first evidence that IpaB 
undergoes a conformational rearrangement upon interaction with the chaperone, IpgC. IpgC may 
hold IpaB in a conformation that prevents membrane interaction. The first detailed analysis of 
IpaB’s structural topology with regard to oligomeric state and membrane interaction was also 
provided. Initial membrane interaction may be localized to an α-helical hairpin region within the 
heart of the hydrophobic domain in the context of the full-length protein. Finally, we showed that 
the C-terminal 85 residues of IpaB are involved in regulating pore formation. One could speculate 
that these 85 residues form a “plug,” that is displaced by tetramer formation prior to membrane 
association. Further studies examining the hydrophobic region and C-terminus of IpaB should 
reveal the subtle structural changes within IpaB that lead to pore formation. 
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CHAPTER VI 
 
 
MATERIALS AND METHODS 
 
Materials: All reagent-grade chemicals were purchased from Thermo-Fisher Scientific 
(Waltham, MA) or Sigma-Aldrich (St. Louis, MO), unless otherwise indicated.  
Buffers and Reagents: See Appendix A for buffer compositions, media and other recipes.  
Bacterial strains, media, and growth conditions (Chapters I, II, and III). Antibiotic 
concentrations for both liquid and solid media growth were 100 µg/ml ampicillin (to select for 
pHS2, pWPsf4, and pET-series constructs) and 34 µg/ml chloramphenicol (to select for pACYC 
constructs). Growth of liquid cultures was at 37°C with shaking at 200 RPM for Shigella and 
Escherichia coli, shaking was 100 RPM for Salmonella. Shigella were grown on tryptic soy agar 
plates containing 0.025% congo red. Congo red is used as an indicator dye because it is known to 
bind to cells with an active T3SS, and is thus used as an indicator of virulence plasmid 
retention.
202
 E. coli and Salmonella were grown on LB plates. All solid media were incubated at 
37°C. 
 
88 
 
Growth and recombinant expression of IpaB/IpgC complexes. ipaB/pET15b was co-
transformed with ipgC/pACYC into Tuner (DE3) competent E. coli cells and grown on a Luria-
Bertani (LB) plate containing ampicillin and chloramphenicol and incubated overnight. A single 
colony was grown in 10 ml LB containing ampicillin and chloramphenicol to generate a 
permanent stock (200 µl 50% glycerol plus 1 ml broth culture) which was stored at -80° C. This 
permanent stock was used to start an overnight 10 ml culture in minimal media, and 1-2 ml of the 
overnight culture was used to inoculate each liter of Terrific Broth (TB; see Appendix A). One 
liter cultures were grown to an OD600 of 0.6-1.0 and moved to a pre-chilled 17°C shaking 
incubator for 45 min to cool down. Protein expression was induced by the addition of 2 ml of 
0.5M Isopropyl-β-D-thiogalactopyranoside (IPTG) and grown overnight (~16 hr) at 17°C with 
shaking at 200 RPM.  
Chemical Crosslinking (Chapters I and II). Chemical cross-linking experiments were used to 
examine the stoichiometry of IpaB-IpgC complex formation (Chapter I) and the oligomeric state 
of IpaB (Chapter II). In chapter I, the homobifunctional thiol-cleavable crosslinking reagent 
Dithiobis[succinimidyl propionate] (DSP; Thermo-Fisher, Rockford, IL) was used for the 
crosslinking experiments in Chapter I. A 12.3 mM working stock of DSP was prepared by 
dissolving 1 mg of DSP in 200 µl dimethylformamide (DMF). Protein concentrations were 10 
µM in the experiments with IpaB
28.226
, IpaB
1.226
 and IpgC.
151
 Protein and cross-linker 
concentrations were optimized for individual proteins, but these conditions provided a good 
starting point. Samples (50 µl) of 10 µM IpaB
1.94
/IpgC, IpaB
1.226
, IpaB
28.226 
and IpgC were 
prepared. To determine if IpaB and IpgC formed a discrete complex in vitro, samples were made 
to contain IpaB and IpgC at a molar ratio of 1:2. DSP (0.68 µl aliquot of 12.3 mM stock) was 
added to the 50 µl samples, mixed, and incubated at room temperature for 30 min. 25 µl of 3x 
SDS-PAGE sample buffer was added to quench the crosslinking reaction. Reactions were split 
into two aliquots and dithiothreitol (DTT) was added at a final concentration of 50 mM to one 
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aliquot of each reaction to reverse the cross-linking reaction. Samples were separated on a 4-20% 
TGX gradient gel (Biorad, Hercules, CA) and stained with Oriole fluorescent gel stain (Biorad) 
for 90 min. After staining, gels were soaked in pure water for 45 min. to remove excess stain. The 
proteins used for the above experiments were expressed recombinantly in pT7HMT, which 
encodes a 6x-His-tag on the N-terminus of the protein.
203
 pT7HMT encodes a Tobacco etch virus 
(TEV) protease site immediately downstream of the His-tag. The 6x-His-tag was removed using 
TEV protease prior to cross-linking. 
 In Chapter II, full-length IpaB and truncated forms of IpaB were cross-linked with the 
water-soluble, homobifunctional, non-cleavable cross-linking agent bis[sulfosuccinimidyl] 
suberate (BS3) was used. BS3 was selected because it does not diffuse across lipid bilayers. A 10 
mM working stock of BS3 was prepared in 1x PBS. Proteins were diluted to 5 µM in PBS with or 
without 4.4 mg/ml of liposomes and incubated for 10 min. at room temperature. After BS3 was 
added (final concentration = 84 µM) the reactions were incubated 10 min. at room temperature. 
The reaction was stopped by the addition of 3x SDS-PAGE sample buffer and 50 mM DTT. 
Samples were boiled, run on 4-20% SDS-PAGE gels and stained with Oriole fluorescent gel stain 
(Biorad) as above. 
Förster Resonance Energy Transfer (FRET) (Chapter I). 
 FRET was used to detect conformational changes in IpaB’s N-terminal domain. The two 
fluorophores used were tryptophan and Alexa350. This dye pair has an Ro of 22 Å.
204
 IpaB’s N-
terminal domain has a native Trp residue at position 105 (W105). W105 was used as the donor 
fluorophore, and Alexa350 was used as the acceptor. Alexa350-C5-maleimide was used to label 
IpaB
28.226
 and IpaB
1.226
 that were modified to have a Cys residue at either the N or C-terminus 
(IpaB
C28-226
, IpaB
N28-226
, IpaB
C1-226
, and IpaB
N1-226
). Alexa350-labeled proteins were called “donor-
acceptor” (DA), and proteins lacking the extrinsic label were called “donor” (D).  
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Fluorescence spectra were collected with a Jobin-Yvon FluoroMax-4 spectrofluorometer. 
Samples were excited at 295 nm. Fluorescence emission spectra were collected from 300-400 nm 
using a signal integration time of 1 sec. Both sets of slits were adjusted to 2.5 nm. Samples 
containing 1 µM of D or DA were prepared in the presence and absence of 1 µM IpgC to 
determine if IpgC altered the FRET efficiency (E) as calculated by: 
Equation 1: E = 1 – FDA / FD 
Where FDA is the peak W105 fluorescence intensity of DA samples, and FD is the peak 
W105 fluorescence intensity of D samples. Distances between the donor probe and acceptor 
probe were calculated using:  
Equation 2: r = R0((1 / E) – 1)
1/6
  
Where r is the calculated distance separating the donor and acceptor probes, E is the 
FRET efficiency, and R0 is the distance unique to this FRET pair at which 50% FRET occurs, 
which is 21 Å.
204
  
Generation of IpaB Mutants (Chapters I and II).  
Generation of IpaB Cys mutants for expression in S.flexneri SF620 and E. coli Tuner (DE3) 
(Chapter II). Primers containing GAGAGAGAG and a BsrGI restriction site were designed to 
generate the following point mutations (for primer sequences see Appendix B): S19C, S58C, 
S107C, S149C, S237C, A254C, A353C, A420C, S486C, A502C, and S519C. S107C and S149C 
required the use of BssHII and AflII, respectively. The mutations were generated by inverse PCR 
using ipaB/pHS2 as a template, followed by digestion with the enzyme indicated above. The 
linear plasmids were then ligated using Clonables 2X ligation premix (EMD-Millipore, 
Darmstadt, Germany) and used to transform Nova Blue E. coli cells (EMD-Millipore). 
Nucleotide sequences of purified plasmids were verified by sequencing at the Oklahoma State 
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University Biochemistry and Molecular Biology Recombinant DNA and Protein Core Facility 
(Stillwater, OK). ipaB mutants in pHS2 were introduced into the ipaB null strain SF620 by 
electroporation. Transformed Shigella were plated on trypitcase soy agar containing 0.025% 
congo red and 100 µg/µl ampicillin. Congo red is used to differentiate between colonies that have 
retained the virulence plasmid and those that have not.
202
 pHS2 contains a beta-lactamase cassette 
which allowed selection of only those cells that harbored the desired plasmid.  
ipaB mutants were subcloned from pHS2 into pET15b for recombinant protein 
expression. ipaB mutants in pHS2 were digested with NdeI and BamHI and then separated from 
the vector on a 1% agarose gel. Bands corresponding to ipaB were cut out and purified from the 
gel using the Qiagen gel-extraction kit (Venlo, The Netherlands). The gel-purified, NdeI/BamHI 
digested ipaB genes were then ligated into NdeI/BamHI-digested pET15b using Clonables 2x 
ligation premix (EMD Millipore) according to the manufacturer’s protocol, used to transform 
NovaBlue E. coli cells, and grown on LB agar with 100 µg/ml ampicillin. Selected transformants 
were screened for insertion of a gene by colony PCR using T7 promoter and T7 terminator vector 
primers. Colonies that screened positive were sequence-verified as above to ensure that no 
mutations occurred during subcloning. 
Generation of truncated forms of ipaB mutants for expression in Tuner (DE3). 5’-phosphorylated 
primer pairs were designed to generate IpaB
11-312
, IpaB
11-357
, and IpaB
11-390
. An additional ipaB 
mutant covering residues 11-580 included a TEV recognition site after residue 495 (IpaB
11-580 TEV 
495
), because expression of IpaB
11-495 
was not possible. IpaB
11-580 TEV 495
 was generated via two-
steps. First, IpaB
11-580
 was generated. The TEV site was introduced using primers encoding the 
TEV site, with the forward primer encoding the first four residues of the TEV recognition 
sequence and the reverse primer encoding the final three residues (for primer sequences see 
Appendix B). The resulting pWPSF4 constructs were verified by sequencing. ipaB was then 
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subcloned from pWPSF4 into pET15b, and along with ipgC/pACYC, was used to co-transform 
E. coli Tuner (DE3) for protein expression. 
Limited proteolysis. Subtilisin A was purchased from Sigma (Cat # P5459; CAS #: 9014-01-1; 
EC #: 3.4.21.62). A working stock of 1:1000 protease was generated by serial 1:10 dilutions in 
phosphate-buffered saline (PBS). Several final concentrations of protease were surveyed to 
identify the optimal concentration for each protein of interest. For IpaB, 1:80,000 worked best; 
for IpaD, 1:160,000 was best. Ten µl of 3x SDS-PAGE sample buffer and 1 µl of 1.5 M DTT 
were added to pre-labeled tubes and placed in the thermocycler on the “hot-kill” cycle (which is 
an infinite hold at 99° C). This way, 20 µl samples can be taken from a single source reaction and 
stopped immediately. Monomeric and oligomeric IpaB were diluted to 6 µM in PBS and 
incubated for 10 min at room temperature with 4.4 µg/µl of liposomes or an equivalent volume of 
buffer. Protease was added to the specified final dilution and mixed. 20 µl samples were removed 
from the digestion at the specified time points and immediately added to boiling SDS-PAGE 
sample buffer for 10 min. The samples were separated on a 12% polyacrylamide gel and stained 
with Coomassie R250. After destaining, the gels were imaged first on an Alpha Imager and then 
equilibrated with pure water and imaged on an Odyssey infrared imager (LI-COR, Lincoln, NE) 
using the 700 nm channel and a focus offset of 0.5 mm to obtain high-resolution images.  
Liposome Preparation (Chapters I, II, and III). All lipids were purchased from Avanti Polar 
Lipids (Alabaster, AL) and maintained in chloroform at 25 mg/ml at -20° C. For specific recipes 
and notes regarding lipid storage (for recipes see Appendix A). Lipids in chloroform were used 
within 6 months, after which they were replaced. Lipid formulations contained 66.5 mol% DOPC 
(1,2-dioleoyl-sn-glycero-3-phosphocholine), 23.5 mol % DOPG (1,2-dioleoyl-sn-glycero-3-
[phosphor-rac-(1-glycerol)]), and 10 mol% cholesterol. Lipids dissolved in chloroform were 
combined in a 1.5 ml tube and were dried using a gentle nitrogen stream. Films were then 
completely dehydrated using a vacuum centrifuge (SpeedVac), using the “medium” drying rate 
93 
 
for 3 hr. The lipid films were then rehydrated for 30 min in a volume of PBS to bring the lipid 
concentration to 8.7 mg/ml. Rehydrated lipid films were sonicated using a probe sonicator 3-9x 
(depending on the rehydration volume) for 10 sec on intensity 2, or placed in the sonicator bath 
for 30-60 min. The multilamellar liposome suspensions were then extruded by 20 passes through 
a 100-nm pore-sized membrane (GE Healthcare, Pittsburgh, PA) using an Avanti Mini-extruder 
(Avanti Polar Lipids). Liposomes were stored at 4° C until use. 
Liposome Flotation Assay (Chapter II). 65% sucrose was prepared and sterile filtered prior to 
beginning the experiment. The concentration of sucrose was verified by measuring the refractive 
index. Monomeric or oligomeric IpaB was used at a concentration of 0.4 mg/ml. Proteins were 
incubated at room temperature for 15 min. with 4.4 mg/ml liposomes or an equal volume of PBS. 
Sucrose was added to a final concentration of 30% and 190 ul of this was added to the bottom of 
an 11 mm x 30 mm ultracentrifuge tube. One ml of 20% sucrose was layered on top of the 30% 
sucrose layer, and then 150 µl of PBS was layered on top. The tubes were then balanced to within 
1 mg of each other by adding PBS to the top layer. Tubes matched by empty weight were used to 
minimize adjustments. The tubes were spun in an Ultima TL (Beckman-Coulter, Indianapolis, 
IN) using the TLS-55 rotor at 54,000 RPM (210,000 x g) at 4°C for 1 hr. The acceleration rate 
was set to 3 and the deceleration rate was set to 0. Both the ultracentrifuge and the TLS-55 rotor 
were pre-chilled to 4°C. The top 150 µl fraction was collected with a micropipet, and the bottom 
fraction was collected by carefully puncturing the bottom of the tube with a 21-gauge needle. 
Fractions were collected from the middle layer after the bottom fraction was collected. Fractions 
were run on 12% gels and stained with Oriole.  
Proteolysis followed by flotation and trichloroacetic acid (TCA) precipitation (Chapter II). 
To further define which parts of IpaB’s sequence interact with liposomes, IpaB was 
proteolytically cleaved into large domain-sized products. These products were then used in 
liposome flotation analysis and concentrated by precipitation with TCA. In a total volume of 250 
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µl, monomeric IpaB was diluted to 12 µM in PBS. Subtilisin (3.13 µl of 1:1000 working stock) 
was added and the reaction incubated 30 sec. at room temperature. The protease inhibitor 4-(2-
Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF; 50 µl of 100 mM working stock) 
was added to the reaction, vortexed immediately, and placed on ice for 10 min. AEBSF does not 
immediately stop the proteolytic digestion, therefore, this incubation on ice helps to slow the 
digestion while AEBSF binds. Liposomes (180 µl of 8.7 mg/ml stock) were combined with 70 µl 
of the inhibited proteolytic reaction and incubated at room temperature for 10 min. Sucrose was 
added to a final [sucrose] of 30%, and the entire volume was layered onto the bottom of an 11 
mm x 30 mm ultracentrifuge tube. One ml of 20% sucrose was layered on top of the 30% sucrose, 
and topped with 200 µl PBS. The sucrose cushions were spun in an ultracentrifuge as described 
above in “Liposome Flotation Assay.” One 200 µl sample was taken from the top of the cushion 
using a micropipet, and the bottom fraction (~0.5 ml) was collected as described above. Most of 
the 20% sucrose cushion contained no protein, except for the final ~200 µl (the portion of the 
20% layer that was closest to the PBS layer). This part of the 20% sucrose layer (referred to as 
“middle”) contains residual top layer components that were not collected by pipetting. The top 
and middle fractions were not pooled, even though they appeared to contain similar products. 
 To obtain useful amounts of protein for mass spectrometric (MS) analysis, it was 
necessary to concentrate the products recovered from the flotation by trichloroacetic acid (TCA) 
precipitation. This is a modified version of the standard Picking lab TCA precipitation. Top, 
middle, and bottom fractions from separate ultracentrifuge tubes were pooled to obtain three 
“master” pools: top, middle, and bottom. One ml aliquots of the pools were dispensed into 1.5 ml 
microcentrifuge tubes on ice, and 100% TCA was added to the samples at a final concentration of 
10%. The samples were incubated for at least 1 hr. on ice, and then spun in a refrigerated tabletop 
microcentrifuge at 17,000 x g for 30 min. The supernatant was discarded, and the samples were 
washed with 5% TCA followed by centrifugation at 17,000 x g for 15 min. The pellets were next 
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washed with ice-cold acetone twice at 17,000 x g for 15 min. The tubes were then inverted to dry, 
and were resuspended in a minimal volume of 3x SDS-PAGE sample buffer. The top fractions 
formed a compact, white pellet at the bottom of the tube (lipids), and this pellet sometimes still 
contained a small amount of TCA, causing the pH indicator in the sample buffer to turn from blue 
to yellow. In these cases, small volumes of dilute NaOH were added to the samples, along with 
additional 3x SDS-PAGE sample buffer. A small amount of 10% SDS was added to help dissolve 
the compact white pellet.  
Protein Purification (Chapters I and II). Bacteria were pelleted by centrifugation at 5000 RPM 
in a Sorvall F9-4x1000y for 20 min. The bacteria were resuspended on ice in 100 ml of 1x His-
tag binding buffer per liter of clarified culture. The bacteria were lysed by a single pass through a 
Microfluidics M110L microfluidizer at 100 PSI external pressure and the resulting lysate was 
clarified by centrifugation at 22,000 x g for 30 min. The soluble fraction was retained and 
purified using immobilized metal-affinity chromatography (IMAC) on a custom AKTA explorer 
fast-protein liquid chromatography (FPLC) system (GE Healthcare). Protein-containing fractions 
were evaluated by SDS-PAGE. The most pure fractions were collected and concentrated to 5-20 
ml, depending on the starting culture volume. To further purify the IpaB/IpgC complex away 
from degradation products and impurities, the concentrated protein was buffer-exchanged into 
hydrophobic interaction buffer A (See Appendix A for recipes) using pre-packed PD-10 buffer 
exchange columns (GE Healthcare) following the manufacturer’s protocol. The eluate was 0.45 
µm filtered and further purified by hydrophobic interaction chromatography (HIC) using a 5 ml 
butyl-hp column (GE Healthcare). The proteins were eluted from the butyl column by a 20 
column-volume gradient of HIC buffer “B,” which contains no ammonium sulfate (20 mM 
NaPO4, pH 7.0). The elution gradient target concentration of buffer B was 80%. Peak fractions 
were analyzed by SDS-PAGE and relevant fractions were pooled, concentrated, and dialyzed into 
1x binding buffer for separation from the chaperone.  
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Separation of the translocator/chaperone complex using mild detergents. Incubation with mild, 
non-ionic detergents is necessary to release IpaB from IpgC.
144,157
 We have previously shown that 
incubation with N,N-dimethyldodecylamine N-oxide (LDAO) or n-octyl-oligo-oxyethylene 
(OPOE) gives rise to distinct oligomeric states of IpaB, namely a monomer and a tetramer, 
respectively. In this work, IpaB possesses a His-tag and IpgC does not, thus allowing IpgC to be 
washed away while IpaB is retained on an IMAC column. The highly-purified IpaB/IpgC 
complex in 1x binding buffer was split into two populations and bound to separate IMAC 
columns. One column was washed with 30 column volumes (CV’s) of 1x binding buffer with 
0.1% LDAO and the other column was washed with 30 CV’s of 1x binding buffer with 2% 
OPOE. After washing, the columns were sealed and incubated at 4°C with rocking for one hr. 
The columns were washed and incubated a total of three times with the detergent-containing 
binding buffer, and then the concentrations of LDAO and OPOE were reduced to 0.05% and 
0.5%, respectively, for the final wash. IpaB was then eluted using 1x elution buffer with either 
0.05% LDAO or 0.5% OPOE. The eluted protein was analyzed by SDS-PAGE to verify that the 
chaperone was not present. Protein was dialyzed into 1x PBS with either 0.05% LDAO or 0.5% 
OPOE and stored at 4° C until used. 
Gentamicin-Protection Assay (Chapters I and III). Confluent HeLa cell layers were used to 
seed 24-well plates 24 hr. prior to inoculation with bacteria. ipaB mutant strains were streaked 
onto trypticase soy agar containing 0.025% Congo red and 100 µg/ml ampicillin one day prior to 
the assay. Five isolated colonies were inoculated into 10 ml of trypticase soy broth containing 100 
µg/ml ampicillin and 50 µg/ml kanamycin. Cultures were grown to an A600 of ~0.5. While the 
cultures are growing, the HeLa cells were washed with serum-free MEM with 0.45% glucose to 
remove antibiotics. Three µl of bacteria were added to the HeLa cells and the 24-well plate was 
centrifuged at room temperature at 2000 x g for 5 min. The centrifugation step facilitates contact 
between the HeLa cells and the bacteria. The bacteria were incubated with the HeLa cells for 30 
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min at 37°C. The media was aspirated and the cells washed 3x with MEM containing 5% calf 
serum and 50 µg/ml gentamicin, and then incubated for 2 hr in the gentamicin-containing media. 
After the 2-hr incubation, the cells were washed with MEM-glucose and then overlaid with 0.5% 
agar to lyse the cells, followed by an overlay with 2x LB agar. The 24-well plates were incubated 
overnight at 37°C and colonies representing invasive bacteria were counted.  
Contact-Mediated Hemolysis: ipaB mutants were grown overnight on TSA-CR and inoculated 
into 10 ml of trypticase soy broth containing 100 µg/ml ampicillin and 50 µg/ml kanamycin. The 
bacteria were grown to an A600 of 0.5, pelleted at 3000 x g, and resuspended with 200 µl 
phosphate-buffered saline (PBS). Three ml defibrinated sheep blood (Colorado Serum, CO) was 
diluted with 40 ml PBS and centrifuged to collect the red blood cells (RBCs). RBCs were 
resuspended in 3 ml PBS and 50 µl/well distributed to a 96-well plate. A 50 µl aliquot of each 
mutant strain was added to each of three wells, and then the 96-well plate was centrifuged at 2200 
x g for 15 min at room temperature. The plate was incubated at 37°C for 1 hr. The bacteria were 
sheared from the RBCs by vigorously resuspending the pellet in each well with 100 µl of ice-cold 
PBS. The plate was again centrifuged at 2200 x g for 15 min at 10°C. 100 µl of the supernatant 
from each well was transferred to a fresh well and the released hemoglobin measured by the 
absorbance at 545 nm using a Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA). 
Overnight Secretion followed by Western blot analysis: A 10 ml culture of each ipaB mutant 
was grown as above, except the culture was incubated overnight. Bacteria were pelleted by 
centrifugation at 3000 x g and the supernatant was transferred to a 30 ml Corex centrifuge tube on 
ice. The bacterial pellet was resuspended in 1 ml of water and frozen. One ml of 100% TCA was 
mixed into the bacterial supernatant, followed by a one hr. incubation on ice. The samples were 
then spun at 11,800 x g for 15 min. The samples were washed with ice-cold 5% TCA and 
centrifuged as above. Next, the samples were washed twice with ice-cold acetone. After the final 
wash, the Corex tubes were inverted and the acetone completely evaporated. Once dry, the pellets 
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were resuspended with 400 µl PBS plus 200 µl 3x SDS-PAGE sample buffer plus 20 µl 1.5 M 
DTT. For quantitative purposes, the secreted proteins were analyzed by Western blot. Proteins 
were transferred to a polyvinylidene difluoride (PVDF) membrane using a Bio-Rad semi-dry 
blotter (15V, 37 min.). Membranes were blocked with Odyssey blocking buffer (LiCor, Lincoln, 
NE) diluted 1:1 with PBS for 1 hr. at room temperature while gently shaking. Then membranes 
were incubated overnight with IgG purified from rabbit anti-sera directed against IpaB, IpaC, and 
IpaD, diluted (1:1000) in blocking buffer prepared as above. The membranes were washed three 
times with PBS containing 0.05% Tween-20 to remove excess primary antibody. Alexa-Fluor 680 
goat α-rabbit was diluted (1:10,000) as above. The secondary antibody was allowed one hr. to 
interact with the primary antibody-labeled membranes. Finally, the membranes were washed as 
above and then imaged on an Odyssey Infrared imager (LiCor).  
Fluorescence Labeling of IpaB. To facilitate optimal labeling, IpaB was concentrated to at least 
2 mg/ml prior to labeling. Monomeric or oligomeric IpaB was dialyzed into labeling buffer (see 
Appendix A) plus 5 mM Tris[2-carboxyethyl] phosphine (TCEP) pH: 7.0 and with either 0.05% 
LDAO or 0.5% OPOE overnight to reduce Cys residues for labeling. The TCEP concentration 
was adjusted to 1 mM by dialysis immediately before labeling. IpaB was removed from dialysis, 
0.45 µm filtered and the concentration determined by absorbance at 280 nm. Enough fluorescein-
5-maleimide (FM; Molecular Probes, Eugene, OR) to provide at least a 10-fold molar excess of 
FM:IpaB was dissolved in a minimal amount of dimethylformamide (DMF). 4 mg of IpaB was 
aliquoted to a small test tube, along with a 0.25 in. stir bar. The following steps were performed at 
room temperature while stirring. FM was added dropwise to IpaB and the test tube was purged 
with N2 for 10 min to remove molecular oxygen. The labeling reaction was then sealed with 
paraffin paper and incubated for 2 hr. Free dye was removed from IpaB using an IMAC column. 
Binding buffer (8x) was added to the labeling reaction to equilibrate the protein with the IMAC. 
FM-labeled IpaB (FM-IpaB) was then bound to the IMAC and washed with at least 250 ml of 
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binding buffer plus either 0.05% LDAO or 0.5% OPOE and eluted as above. Peak fractions were 
pooled, concentrated to 2.5 ml and then buffer exchanged into 1x PBS with either 0.05% LDAO 
or 0.5% OPOE.  
Concentrations were determined for the FM-labeled proteins using UV-Vis absorbance 
spectroscopy. The A280 must be corrected to account for the absorbance of light at 280 nm by the 
fluorescent probe. The A280 and A494 of FM-labeled proteins were collected. The A280 was 
corrected using the following equation: 
Equation 6: A280 Observed – (CF * A494) = A280 Actual  
Where CF (CF = 0.3 for FM) is the correction factor, A280 Observed is the experimentally determined 
absorbance at 280 nm, A494 is the experimentally determined absorbance at 494 nm, and A280 Actual 
is the absorbance at 280 nm corrected for FM absorbance. A280 Actual was used to calculate the 
protein concentration using the Beer-Lambert Law.  
Equation 7: A = εcl 
Where A represents the absorbance value, ε represents the molar extinction coefficient, c 
represents the molar concentration, and l is the path length of the cuvette (1 cm). 
The degree of labeling (DOL) was calculated using the following equation: 
Equation 8: FM concentration (M) / Protein concentration (M) * 100 = DOL (%) 
Fluorescence Quenching of fluorescein-labeled IpaB with potassium iodide. Emission spectra 
were collected using a Jobin-Yvon FluoroMax-4 spectrofluorometer (Edison, NJ). Samples were 
excited with 493 nm light using 5 nm slits. Emission was detected from 500-560 nm with 2.5 nm 
slits and an integration time of 0.1 sec. Fluorescein maleimide-labeled IpaB (FM-IpaB) was 
diluted into PBS with or without 0.15 mg/ml of liposomes to a final volume of 600 µl. The first 
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scan of each sample was in the absence of potassium iodide (KI), and then KI (KI stock = 4 M) 
was titrated 10 µl at a time into the sample, mixed thoroughly, and scanned again. Fo/F values 
were determined from the spectra using the observed emission maximum (Emax) of 518 nm. Fo/F 
values were plotted as a function of iodide concentration using an x,y scatter plot in Origin Pro 
9.0 (OriginLab Corp., Northampton, MA). All subsequent analyses were done in Origin Pro 9.0. 
The Stern-Volmer equation (Equation 3) was fit to the data.
205
  
Equation 3: Fo/F = 1+ KSV[KI] 
F0 is the fluorescence intensity at 515 nm prior to the addition of KI, and F is the fluorescence 
intensity at 515 nm after adding the specified concentration of KI. The Stern-Volmer quenching 
constant, KSV, is equal to the slope and was calculated by Origin Pro 9.0. 
Calculation of the Protection Index (PI). A protection index was calculated by the following 
equation as a means to visualize differences in the availability of a particular residue as a result of 
either oligomer formation or liposome interaction.
163
  
Equation 4: KSV 
Monomer
 / KSV 
Tetramer
 = Protection Index (PI)  
We also calculated a protection index to determine how the solvent accessibility of 
residues was affected by the presence or absence of liposomes. This is the ratio of the KSV 
–Vesicles
 
to the KSV 
+Vesicles
 (Equation 5). 
Equation 5: KSV 
–Vesicles
 / KSV 
+Vesicles
 = Protection Index (PI)   
 The PI’s were plotted as column charts in Origin Pro with error bars representing the 
standard deviation. 
.
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APPENDICES 
 
 
 
Appendix A: Recipes 
 
 
Buffers: 
 
Agarose gel for DNA electrophoresis 
25 ml 1X TAE 
15 µl 6 mM Ethidium bromide 
0.3 g agarose (electrophoresis grade) 
 
1X TAE (running buffer for agarose gel electrophoresis) 
4.84g Tris 
1.142ml Glacial acetic acid 
2ml 0.5 M EDTA 
Q.S. to 1 L 
 
Hydrophobic Interaction Chromatography (HIC) Buffer A 
20 mM NaPO4 
1M ammonium sulfate  
pH: 7.0 
 
HIC Buffer B 
20 mM NaPO4 
pH: 7.0 
 
IMAC Binding Buffer 
20 mM Tris-HCl 
500 mM NaCl 
5mM imidazole 
pH: 7.9 
 
IMAC Charge Buffer 
50 mM NiSO4 
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IMAC Elution Buffer 
20 mM Tris-HCl 
500 mM NaCl 
400 mM imidazole 
pH: 7.9 
 
IMAC Strip Buffer 
20 mM Tris-HCl 
500 mM NaCl 
100 mM EDTA 
pH: 7.9 
 
IMAC Wash Buffer 
20 mM Tris-HCl 
500 mM NaCl 
60 mM imidazole 
pH: 7.9 
 
Phosphate-Buffered Saline (PBS) 
130 mM NaCl 
10 mM Na2HPO4 
1.5 mM K2HPO4  
3 mM KCl 
 
12% SDS-PAGE Separating Gel (Sufficient for two gels) 
3.00 ml diH20 
2.50 ml 1.5 M Tris-HCl, pH 8.8 
100 μl 10% (w/v) SDS 
4.00 ml 29:1% (w/v) acrylamide:bisacrylamide 
0.15 ml 10% (w/v) ammonium persulfate (APS) 
10 μl N,N,N′,N′-Tetramethylethylenediamine (TEMED) 
 
15% SDS-PAGE Separating Gel (Sufficient for two gels) 
2.50 ml diH20 
2.50 ml 1.5 M Tris-HCl, pH 8.8 
100 μl 10% (w/v) SDS 
5.00 ml 29:1% (w/v) acrylamide:bisacrylamide 
0.15 ml 10% (w/v) APS 
10 μl TEMED 
 
5% SDS-PAGE Stacking Gel (Sufficient for two gels) 
2.85 ml diH2O 
1.25 ml 0.5 M Tris-HCl, pH 6.8 
50.0 μl 10% (w/v) SDS 
1.00 ml 29:1% (w/v) acrylamide:bisacrylamide 
0.2ml 10% (w/v) APS 
15μl TEMED 
 
Maleimide-Labeling buffer: 
 To prepare proteins to be labeled with sulfhydryl-reactive dyes. 
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50 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) 
150 mM NaCl 
5 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 
pH: 7.0 
 
SDS-PAGE destain 
5% (v/v) methanol 
7.5% (v/v) glacial acetic acid 
 
SDS-PAGE running buffer 
2.42g Tris 
14.41g glycine 
1.0g SDS 
Q.S. to 1 L 
 
SDS-PAGE stain  
0.1% (w/v) Coomassie Brilliant Blue R-250 
5% (v/v) methanol 
7.5% (v/v) glacial acetic acid 
 
Solution A 
8.0g NaCl 
0.4g KCl 
0.5g NaHCO3 
1.0g glucose 
Q.S. to 1 L and filter sterilize. 
 
 
Media: 
 
20x NPS (1L): 
 (NPS = 100 mM PO4, 25 mM SO4, 50 mM NH4, 100 mM Na, 50 mM K) 
In a graduated cylinder, combine (in the below sequence) and stir until dissolved: 
800 ml nanopure H2O 
66 g (NH4)2SO4 
136 g KH2PO4 
142 g Na2HPO4 
Q.S. to 1 L 
 
Congo Red agar 
37g Tryptic soy agar 
0.03% Congo Red 
Q.S. to 1 L 
 
Luria-Bertani (LB) Broth 
25.0 g LB broth (ready-made mix)  
Q.S. to 1 L 
 
LB Agar  
37.0 g LB agar (ready-made mix) 
Q.S. to 1 L 
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Dulbecco’s Modified Eagle Medium (DMEM) 
9.53g DMEM 
2.2g NaHCO3 
Q.S. to 1 L and filter sterilize 
 
DMEM plus Calf Serum (CS) 
9.53g DMEM 
2.2g NaHCO3 
100ml calf serum 
Q.S. to 1 L and filter sterilize 
 
DMEM plus CS plus Gentamycin 
9.53g DMEM 
2.2g NaHCO3 
100ml calf serum 
50mg gentamycin 
Q.S. to 1 L and filter sterilize 
  
DMEM plus Glucose 
9.53g DMEM 
2.2g NaHCO3 
4.5g glucose 
Q.S. to 1 L and filter sterilize 
 
Minimal Medium:  
 This bacterial growth medium provides a non-inducing, lactose-free environment and is 
excellent for starter (10 ml) cultures for protein expression.  
 
9.25 ml sterile H2O 
20 µl 1 M MgSO4 
125 µl 40% glucose 
100 µl 25% aspartate 
500 µl 20x NPS  
 
 
Terrific broth (TB): 
To prepare 1L of TB, combine 900 ml of tryptone-yeast (Component A) with 100 ml of 
TB salts (Component B). Components A and B must be prepared and sterilized separately. If 
combined prior to autoclave sterilization, the salts will precipitate. 
 
Component A (tryptone-yeast): 
12 g Tryptone 
24 g Yeast extract 
4 ml Glycerol 
900 ml nanopure H2O 
 
Component B (TB Salts): 
Combine the following in ~600 ml of nanopure H2O: 
125.41 g K2HPO4 
23.12 g KH2PO4 
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Q.S. to 1 L  
 
Tryptic Soy Agar (TSA) 
37g TSA (ready-made mix) 
Q.S. to 1 L 
 
Tryptic Soy Broth (TSB) 
25g TSB (ready-made mix) 
Q.S. to 1 L 
 
Other: 
 
Liposomes:  
66.5 mol% DOPC, 23.5 mol % DOPG, 10 mol% CHOL 
 
Lipid 1x 2x 4x 
DOPC 36.6 µl 73.2 µl 146.4 µl 
DOPG 13.12 µl 26.24 µl 52.5 µl 
Cholesterol 2.71 µl 5.42 µl 10.84 µl 
 
Resuspension volumes (final lipid concentration = 8.735 mg/ml):  
1x: 150 µl 
2x: 300 µl 
4x: 600 µl 
 
Notes: 
 All lipids, except for cholesterol (see below), were purchased from Avanti Polar 
Lipids (Alabaster, AL) as 25 mg/ml chloroform preparations. 
 Cholesterol was purchased from Sigma-Aldrich. 
 Upon receipt, lipids were removed from glass ampoules, aliquoted into 2 ml amber 
glass vials with screw-top Teflon-lined lids and stored at -20° C. 
 1x lipid films were used for making SRB-filled liposomes.  
 2x and 4x films were prepared when large volumes of liposomes were needed, such 
as for the quenching experiments in Chapter II or liposome flotation assays.  
 
Protease Inhibitor 
 Dissolve 4-(2-Aminoethyl)-benzenesulfonylfluoride hydrochloride (AEBSF) in 
nanopure water at a concentration of 100 mM.  
 Store 200 µl aliquots at -20° C.  
 AEBSF aliquots were thawed immediately prior to use at room temperature. It is 
not advisable to thaw AEBSF at higher temperatures, because AEBSF’s t1/2 
decreases steeply with increasing temperature. 
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Appendix B: Primer Sequences 
 
To make C19S – Use BsrGI 
B75f – GAG AGA GAG TGT ACA GAG CTT GGA GCA AAT ACT 
B76r- GAG AGA GAG TGT ACA AGT CAA TAT TTT GGC AAG AG 
 
To make S58C– Use BsrGI 
B77f - GAG AGA GAG TGT ACA TCA AAT ATA TTA ATC CCT GAA  
B78r - GAG AGA GAG TGT ACA GTG TGC ATT AGT TGT ATT AAT 
 
To make S107C – Use BssHII 
B79f – GAG AGA GAG GCG CGC CAG CAA AAA AAC CTA GAA TT 
B80r - GAG AGA GAG GCG CGC CTG TTG CTG GCA CTT CCA AGC AGT AAT TTT A 
 
To make S149C – Use AflII 
B81f – GAG AGA GAG CTT AAG AAC GCA GAT TGT AAA ATA AAA GAC CTA GAA 
AAT 
B82r – GAG AGA GAG CTT AAG TTT ATT AAT TTG TTT TTC ATA GT 
 
To make S237C – Use BsrGI 
B83f – GAG AGA GAG TGT ACA CAG CAG AAA TCA TTA AC 
B84r – GAG AGA GAG TGT ACA TAG CTG TTC AGC AGA TG 
 
To make A254C- Use BsrGI 
B85f – GAG AGA GAG TGT ACA TTT ATT CAA CTA GTT GGA 
B86r – GAG AGA GAG TGT ACA CAT CAA TTG AGT AAC ACT G 
 
To make A353C- Use BsrGI 
B87f – GAG AGA GAG TGT ACA GGC AAT TCC TTC ATG GA 
B88r – GAG AGA GAG TGT ACA TGC TTG TAC TAT AGC ATC 
 
To make A420C- Use BsrGI 
B89f – GAG AGA GAG TGT ACA GTT GGT AAA CAG GCA G 
B90r – GAG AGA GAG TGT ACA TAC GAG AAC GAC TGC TG 
 
To make S486C- Use BsrGI 
B91f – GAG AGA GAG TGT ACA CAT TTA AAC CAA GCA GT 
B92r – GAG AGA GAG TGT ACA AAT AAT TTG TTT GGA TAT TAC T 
 
To make A502C- Use BsrGI 
B93f – GAG AGA GAG TGT ACA CAA GCG GGA GGA AGT 
B94r – GAG AGA GAG TGT ACA AGA GTT AAC ACT TTC TCC T 
 
To make S520C- Use BsrGI 
B95f – GAG AGA GAG TGT ACA AAT CTA GCA GAC CTG AC 
B96r – GAG AGA GAG TGT ACA CGC GCT GTT CTG GAA A 
 
Primers used to insert TEV sites. The underlined bases indicate the sequence encoding the TEV 
site. 
 
To insert a TEV site prior to residue 58.  
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B302F- PO4 TAT TTC CAA GGA TCA ACT TCA AAT ATA TTA ATC 
B303R- PO4 AAG ATT TTC GAG TGC ATT AGT TGT ATT AA 
 
To insert a TEV site prior to residue 82. Bold T in B304F’s TEV site is a silent mutation in the 
wobble position to reduce hairpin 
 
B304F- PO4 TAT TTT CAA GGA TTA ATT GGA AAC CTT ATT CAA A 
B305R- PO4 AAG ATT TTC AAG CGT TAG TTG GGA ACT T 
 
To insert a TEV site prior to residue 190. Note: the bold T in B306F is a substitution for C in the 
wobble position to reduce hairpin. 
 
B306F- PO4 TAT TTC CAA GGA GAT GCA GCA GTT AAA GAC 
B307R- PO4 AAG ATT TTC TTT TTT GAT AGT GAG TTG TAT T 
 
To insert a TEV site prior to residue 220. 
 
B308F- PO4 TAT TTC CAA GGA GAA ATA GAC TCT TTT TCT GCA 
B309R- PO4 AAG ATT TTC TTT TTC GAG TTG CAT TGA TTT 
 
 
To insert a TEV site prior to residue 312: Note: the bold bases in B310F and B313R are 
substitutions in the wobble position to reduce hairpin. 
 
B310F- PO4 TAT TTT CAG GGA ATA CTT GGG GCA CTT TTA A (52°) 
B311R- PO4 AAG ATT TTC TTT CCC AAC ACA ACC CAT T (54°) 
 
To insert a TEV site prior to residue 495: 
 
B312F- PO4 TAT TTC CAA GGA GGA GAA AGT GTT AAC TCT G (54°) 
B313R- PO4 AAG ATT TTC TAA TAA AAC TGC TTG GTA TAA A (54°) 
To make IpaB 11-312: 
 
B314F- GAG AGA GAG CAT ATG TTT CCT CTT GCC AAA ATA TT 
Use B293R for reverse.  
 
To make IpaB 11-357: 
 
Use B314F for forward. 
B315R- GAG AGA GAG GGA TCC TCA GGA ATT GCC GGT CGC T 
 
To make IpaB 11-390: 
 
Use B314F for forward. 
B316R- GAG AGA GAG GGA TCC TCA GCC CAA GCC TTC GAG CA 
 
To make IpaB 11-495: 
 
Use B314F and B292R 
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